WO2004085425A1 - Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors - Google Patents
Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors Download PDFInfo
- Publication number
- WO2004085425A1 WO2004085425A1 PCT/US2004/008809 US2004008809W WO2004085425A1 WO 2004085425 A1 WO2004085425 A1 WO 2004085425A1 US 2004008809 W US2004008809 W US 2004008809W WO 2004085425 A1 WO2004085425 A1 WO 2004085425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- optionally substituted
- phenyl
- ylmethoxy
- chloro
- Prior art date
Links
- YRVLIHXIZDLELI-UHFFFAOYSA-N Cc(cc1OCCN(CC2)CC2N(C)C)ccc1Cl Chemical compound Cc(cc1OCCN(CC2)CC2N(C)C)ccc1Cl YRVLIHXIZDLELI-UHFFFAOYSA-N 0.000 description 5
- 0 CN(C)CCN*1nccc(Oc2ccc3n*(Nc(cc4C(F)(F)F)ccc4Cl)[n]c3c2)n1 Chemical compound CN(C)CCN*1nccc(Oc2ccc3n*(Nc(cc4C(F)(F)F)ccc4Cl)[n]c3c2)n1 0.000 description 4
- JRLPZBPFBQQCRE-UHFFFAOYSA-N CC(C)N1CC(COc2cc(C)ccc2Cl)CC1 Chemical compound CC(C)N1CC(COc2cc(C)ccc2Cl)CC1 JRLPZBPFBQQCRE-UHFFFAOYSA-N 0.000 description 1
- IEAKVOACBVHQHG-IBGZPJMESA-N CC(C)N1[C@H](COc2cc(Nc3nc4cc(Oc5ccnc(C(NC)=O)c5)ccc4[o]3)ccc2Cl)CCC1 Chemical compound CC(C)N1[C@H](COc2cc(Nc3nc4cc(Oc5ccnc(C(NC)=O)c5)ccc4[o]3)ccc2Cl)CCC1 IEAKVOACBVHQHG-IBGZPJMESA-N 0.000 description 1
- LHXBUGCZCPLCBE-UHFFFAOYSA-N CN1CCN(Cc(cc(cc2)Nc([nH]c3c4)nc3ccc4Oc3ncnc4c3cc[nH]4)c2Cl)CC1 Chemical compound CN1CCN(Cc(cc(cc2)Nc([nH]c3c4)nc3ccc4Oc3ncnc4c3cc[nH]4)c2Cl)CC1 LHXBUGCZCPLCBE-UHFFFAOYSA-N 0.000 description 1
- VKILOXQBUNNFSN-UHFFFAOYSA-N CN1CCN(Cc(cc(cc2)Nc3nc4cc(Oc5ccnc6ccccc56)ccc4[nH]3)c2[ClH]C)CC1 Chemical compound CN1CCN(Cc(cc(cc2)Nc3nc4cc(Oc5ccnc6ccccc56)ccc4[nH]3)c2[ClH]C)CC1 VKILOXQBUNNFSN-UHFFFAOYSA-N 0.000 description 1
- MZCRQBOVCGGSLE-UHFFFAOYSA-N CNC(c1nccc(Oc2ccc3[o]c(Nc(cc4)ccc4Br)nc3c2)c1)=O Chemical compound CNC(c1nccc(Oc2ccc3[o]c(Nc(cc4)ccc4Br)nc3c2)c1)=O MZCRQBOVCGGSLE-UHFFFAOYSA-N 0.000 description 1
- ZCCVUGDQCAGCAA-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc1ccc2[o]c(Nc(cc3)ccc3Cl)nc2c1 Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc1ccc2[o]c(Nc(cc3)ccc3Cl)nc2c1 ZCCVUGDQCAGCAA-UHFFFAOYSA-N 0.000 description 1
- XCSZAUIGDXMYEM-UHFFFAOYSA-N Cc(cc1)cc(CN(CC2)CCC2N)c1Cl Chemical compound Cc(cc1)cc(CN(CC2)CCC2N)c1Cl XCSZAUIGDXMYEM-UHFFFAOYSA-N 0.000 description 1
- HVEALYNOVBAPLR-UHFFFAOYSA-N Cc(cc1CN(CC2)CC2N(C)C)ccc1Cl Chemical compound Cc(cc1CN(CC2)CC2N(C)C)ccc1Cl HVEALYNOVBAPLR-UHFFFAOYSA-N 0.000 description 1
- SDRQQRPCXCOIIB-UHFFFAOYSA-N Cc(cc1OCC2N(C)CCC2)ccc1Cl Chemical compound Cc(cc1OCC2N(C)CCC2)ccc1Cl SDRQQRPCXCOIIB-UHFFFAOYSA-N 0.000 description 1
- KEBIZMQVCXHCGN-UHFFFAOYSA-N Cc1c(cc[nH]2)c2ncc1 Chemical compound Cc1c(cc[nH]2)c2ncc1 KEBIZMQVCXHCGN-UHFFFAOYSA-N 0.000 description 1
- ZBCOTWQYKCHKQK-UHFFFAOYSA-N Cc1ncc(C(F)(F)F)cc1 Chemical compound Cc1ncc(C(F)(F)F)cc1 ZBCOTWQYKCHKQK-UHFFFAOYSA-N 0.000 description 1
- HQFYOQKLNWLSKV-UHFFFAOYSA-N FC(c(cc1)ccc1Nc1nc2cc(Nc3c(cccc4)c4ncc3)ccc2[o]1)(F)F Chemical compound FC(c(cc1)ccc1Nc1nc2cc(Nc3c(cccc4)c4ncc3)ccc2[o]1)(F)F HQFYOQKLNWLSKV-UHFFFAOYSA-N 0.000 description 1
- ADNIBVBCYVEKGT-UHFFFAOYSA-N [O-][N+](c(cc1CN2CCCC2)ccc1Cl)=O Chemical compound [O-][N+](c(cc1CN2CCCC2)ccc1Cl)=O ADNIBVBCYVEKGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- FUSED AZOLES SUCH AS 2 , 5-DISUBSTITUTED BENZIMIDAZOLES , BENZOXAZOLES AND BENZO-
- This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis- related disorders.
- Protein kinases represent a large family of proteins which play a central role in the regulation of a wide
- a partial list of such kinases includes abl, Akt, bcr-abl, Blk, Brk, Btk, c-kit, c-met, c-src, c-fms,.
- Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy) , age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis,
- inflammatory disease such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis) , or other chronic inflammatory disorders, such as chronic asthma, arterial or post- transplantational atherosclerosis, endo etriosis, and
- VEGF Vascular Endothelial Growth Factor
- VPF Vascular Permeability Factor
- PDGF PDGF
- PDGF vascular endothelial growth factor
- VEGF receptors are transmembranous receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain.
- Various types of VEGF receptor are known, e.g. VEGFR-1 (also known as flt- 1), VEGFR-2 (also known as KDR) , and VEGFR-3.
- VEGF vascular endothelium
- VEGF expression could explain the occurrence of cerebral edema in patients with glioma.
- Direct evidence of the role of VEGF as a tumor angiogenesis factor in vivo is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGF antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques . All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines in vivo as a result of inhibited tumor angiogenesis.
- Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion. Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.
- VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.
- VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.
- a class of compounds useful in treating cancer and angiogenesis is defined by Formula I
- W and X are independently selected from 0, S(0) n and
- Y 1 and Y 2 are independently selected from 0, S(0) n/ N and NR 4 ; wherein ring A optionally contains a nitrogen atom independently at position 4, 6 or 7 ; wherein n is 0, 1 or 2 ; wherein R is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 5-6 membered heterocyclyl , c) substituted or unsubstituted 9-14 membered fused heterocyclyl , d) substituted or unsubstituted cycloalkyl, and e) substituted or unsubstituted cycloalkenyl , wherein substituted R is substituted with one or more substituents independently selected from halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , oxo, -OR 3 ,
- R 1 is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 4-6 membered heterocyclyl , c) substituted or unsubstituted 9-14 membered fused heterocyclyl , d) substituted or unsubstituted arylalkyl, and e) substituted or unsubstituted heterocyclylalkyl , where substituted R 1 is substituted with one or more substituents selected from halo, -OR 3 , -SR 3 , -
- R 2 is one or more substituents independently selected from H, halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , -S0 2 R 3 , -NR 3 C(0)0R 3 , -NR 3 C(0)R 3 , optionally substituted 3- 6 membered heterocyclyl, optionally substituted phenyl, alkylaminoalkoxyalkoxy, nitro, cyano, oxo, lower alkyl substituted with R 5 ; wherein R 2 is one or more substituents independently selected from H, halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , - NR 3 R 3 , -S0 2 R 3 , -S0 2 NR 3 R 3 , -NR 3 C(0)OR 3 , -
- the invention also relates to compounds of Formula I wherein and X are independently selected from 0 and NR 4 ; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula I wherein W is 0 or NH; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula I wherein X is 0 or NH; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula I wherein W is NH; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula I wherein Y 1 and Y 2 are independently selected from 0, S, N, and NR 4 ; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula I wherein Y 2 is selected from 0, S, and NH; wherein Y 1 is N; and wherein dashed line b indicates a double bond; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula I wherein R is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C 3 - 6 -cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR 3 , oxo, -SR 3 , -S0 2 R 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , -NH(C ⁇ - C 4 alkylenylR 3 ) , - (C 1 -C 4 alkylenyl)NR 3 R 3 , -S0 2
- R 0 R optionally substituted C 4 _ 6 -cycloalkyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl-C ⁇ _6- alkylenyl, optionally substituted 5-6 membered heterocyclyl- Ci-C ⁇ -alkylenyl, 5-6 membered heterocyclyl-C 2 _C 6 -alkenylenyl, C ⁇ _ 4 -alkyl, cyano, C ⁇ _ 4 -hydroxyalkyl, nitro and C ⁇ - 4 -haloalkyl ; wherein R e and R f are independently selected from H and C ⁇ _ 2 - haloalkyl; wherein R 7 is selected from H, C ⁇ _ 3 -alkyl, optionally substituted phenyl-C ⁇ _ 3 -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C
- the invention also relates to compounds of Formula I wherein R is a substituted or unsubstituted ring selected from phenyl, indanyl, tetrahydronaphthyl, naphthyl, cyclohexyl , indazolyl , indolyl , 2,1,3-benzothiadiazolyl , isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 2-oxo-l, 2-dihydroquinol- 7-yl, 1-oxo-l, 2 , 3 , 4-tetrahydro-isoquinolyl, 2 , 3-dihydro-l, 1- dioxo-benzo [d] isothiazolyl, isoindolyl, 2 , 3-dihydro-lH- indolyl , naphth
- R is ; wherein R x is selected from bromo, chloro, methyl, "ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl , 1, 1-di (trifluoromethyl) -1-hydroxymethyl, trifluoromethoxy, difluoromethoxy, isopropoxy, methoxy and ethoxy; and wherein R y is selected from 4-methylpiperazinylsulfonyl, morpholinylmethyl, 4-methylpiperazinylmethyl, 4- methylpiperazinylpropyl, 4-isopropylpiperazinylmethyl, 4- methylpiperidinylmethyl , 4-aminopiperidinylmethyl, 4- methylamino-piperidinylmethyl , 4-dimethylamino- piperidinylmethyl , 3-dimethylaminopyrrolidin-l-ylmethyl,
- R 1 is selected from substituted or unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms, substituted phenyl, and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R 1 is substituted with one or more substituents independently selected from halo, -OR 3 , -SR 3 , - S0 2 R 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , -S0 2 NR 3 R 3 , - NR 3 C(0)OR 3 , -NR 3 C(0)R 3 , optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, nitro, cyano, C 1 _ 4 -alkylamino-C ⁇ _ 4 -alkoxy, and C ⁇ _ 4 -
- R 1 is a substituted or unsubstituted ring selected from pyrazolyl, triazolyl, pyridyl, pyrimidinyl, triazinyl, pyridazinyl, substituted phenyl, indazolyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzotriazolyl, benzo [1, 3] dioxolyl, pyrrolo [2 , 3-d]pyrimidin-4-yl, 2-oxo-l,3- dihydro-pyrrolo [2 , 3-d]pyridin-4-yl, pyrazolo [2, 3 ,b]pyridin- 4-yl, imidazo [4, 5-b]pyridin-4-yl, 2 , 3-dihydrobenzofuryl, 2- oxo-1, 2-dihydroquinolyl, naphthyridinyl and
- R 1 is a substituted or unsubstituted ring selected from 4-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, phenyl, 5-indazolyl, 4-quinolyl, indolyl, isoindolyl, benzotriazolyl, benzo [1, 3] ioxolyl, pyrrolo [2 , 3-d]pyrimidin- 4-yl, 2-oxo-l, 3-dihydro-pyrrolo [2 , 3-d]pyridin-4-yl, pyrazolo [2,3 ,b]pyridin-4-yl, imidazo [4, 5-b]pyridin-4-yl, pyrrolo [2, 3-b]pyridin-4-yl, 2 , 3-dihydrobenzofuryl, 2-oxo- 1, 2-dihydroquinol-7-yl, and 4-quinozalinyl; wherein
- the invention also relates to compounds of Formula I wherein R 2 is one or more substituents independently selected from H, halo, hydroxy, C ⁇ _ 2 -alkoxy, C ⁇ _ 2 -haloalkoxy, amino, C ⁇ _ 2 -alkylamino, optionally substituted 5-6 membered heterocyclyl-C ⁇ - 2 -alkylamino, aminosulfonyl, C 3 _ 6 -cycloalkyl , optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, C_ 4 -alkyl, cyano, C ⁇ _ 2 -hydroxyalkyl, C ⁇ _ 3 - carboxyalkyl , nitro, C 2 _ 3 -alkenyl, C 2 _ 3 -alkynyl and C ⁇ _ 2 - haloalkyl; in conjunction with any of the above or below embodiments .
- the invention also relates' to compounds of Formula I wherein R 2 is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, nitro, propenyl, propynyl, trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; in conjunction with any of the above or below embodiments.
- R 2 is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, amino, dimethylamino, aminosulfonyl, carboxy
- the invention also relates to compounds of Formula I wherein R 2 is H; wherein R 3 is selected from H, C ⁇ - 4 -alkyl, phenyl, phenyl-C ⁇ _ 4 -alkyl, 4-6 membered heterocyclyl, 4-6 membered heterocyclyl-C ⁇ - 3 -alkyl, C 3 -C 6 cycloalkyl and C ⁇ _ 2 - haloalkyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula I wherein R 4 is independently selected from H, C ⁇ _ 3 -alkyl, phenyl, 5-6 membered heterocyclyl, C 5 -C 6 cycloalkyl, and C ⁇ _ 3 -haloalkyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula I where substituted R 1 is substituted with one or more substituents selected from halo, -OR 3 , -SR 3 , -S0 2 R 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , -S0 2 NR 3 R 3 , -NR 3 C(0)OR 3 , - NR 3 C(0)R 3 , optionally substituted 3-6 membered heterocyclyl, optionally substituted phenyl, nitro, cyano, oxo, and lower alkyl substituted with R 6 ; wherein R 2 is one or more substituents independently selected from H, halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , - NR 3 R 3 , -S0 2 R 3 , -S0 2 NR 3 R 3
- the invention also relates to compounds of Formula I wherein R is a substituted or unsubstituted ring selected from phenyl, indanyl, tetrahydronaphthyl, naphthyl, cyclohexyl, indazolyl, indolyl, 2 , 1, 3-benzothiadiazolyl , isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 2-oxo-l, 2-dihydroquinol- 7-yl, 1-oxo-l, 2, 3 , 4-tetrahydro-isoquinolyl, 2 , 3-dihydro-l, 1- dioxo-benzo [d] isothiazolyl, isoindolyl, 2 , 3-dihydro-lH- indolyl, naphthyridinyl
- the invention also relates to compounds of Formula I wherein R is
- R x is selected from bromo, chloro, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl , pentafluoroethyl , 1 , 1-di (trifluoromethyl) - 1-hydroxymethyl, trifluoromethoxy, difluoromethoxy, isopropoxy, methoxy and ethoxy; and wherein R y is selected from H, 4-methylpiperazinylsulfonyl, trifluoromethyl, morpholinylmethyl, 4-methylpiperazinylmethyl, 3- dimethylaminopyrrolidin-1-ylmethyl , 4- methylpiperazinylpropyl, 4-isopropylpiperazinylmethyl, 4- methylpiperidinylmethyl , 4-aminopiperidinylmethyl, 4- methylamino-piperidinylmethyl , 4-dimethylamino- piperidinyl
- R 1 is a substituted or unsubstituted ring selected from 4-pyridyl, triazolyl, -pyrimidinyl, 4-pyridazinyl, phenyl, 6-indazolyl, 4-quinolyl, indolyl, isoindolyl, benzotriazolyl, benzo [1, 3] dioxolyl, pyrrolo [2 , 3-d] pyrimidin- 4-yl, 2-oxo-l, 3-dihydro-pyrrolo [2 , 3-d]pyridin-4-yl, pyrazolo [2 , 3,b]pyridin-4-yl, imidazo [4, 5-b]pyridin-4-yl, pyrrolo [2 , 3-b]pyridin-4-yl, 2 , 3-dihydrobenzofuryl, 2-oxo- 1, 2-dihydroquinol-7-yl, and 4-quinazoliny
- the invention also relates to compounds of Formula I wherein R 2 is H or Cl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II
- W 1 and X are independently 0 or NH; wherein Y 2 is 0 or NR 4 ; wherein n is 0, 1 or 2 ; wherein R is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 5-6 membered heterocyclyl , c) substituted or unsubstituted 9-13 membered fused heterocyclyl , and d) substituted or unsubstituted cycloalkyl, wherein substituted R is substituted with one or more substituents independently selected from halo, -OR ,
- R 1 is selected from a) unsubstituted or substituted 5- or 6-membered nitrogen-containing heteroaryl, b) unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroaryl, and c) phenyl , where substituted R
- R 2 is one or more substituents independently selected from H, halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , - NR 3 R 3 , -S0 2 R 3 , -S0 2 NR 3 R 3 , -NR 3 C(0)OR 3 , -NR 3 C(0)R 3 , optionally substituted 3- 6 membered heterocyclyl, optionally substituted phenyl, nitro, cyano, oxo, and lower alkyl substituted with R 6 ; wherein R 2 is one or more substituents independently selected from H, halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , - NR 3 R 3 , -S0 2 R 3 , -S0 2 NR 3 R 3 , -NR 3 C(0)OR 3 ,
- the invention also relates to compounds of Formula II wherein W 1 is NH; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein X is 0; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein X is NH; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein Y 2 is NH or NCH 3 ; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein Y 2 is 0; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R is a substituted or unsubstituted ring selected from phenyl , indanyl , tetrahydronaphthyl , naphthyl , cyclohexyl, indazolyl, indolyl, 2,1, 3-benzothiadiazolyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 2-oxo-l, 2-dihydroquinol- 7-yl, 1-oxo-l, 2, 3, 4-tetrahydro-isoquinolyl, 2 , 3-dihydro-l, 1- dioxo-benzo[d] isothiazolyl, isoindolyl, 2 , 3-dihydro-lH- indolyl , naphthyridinyl
- the invention also relates to compounds of Formula II
- R is ; wherein R x is selected from bromo, chloro, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, 1, 1-di (trifluoromethyl) -1-hydroxymethyl, trifluoromethoxy, difluoromethoxy, isopropoxy, methoxy and ethoxy; and wherein R ⁇ is selected from 4-methylpiperazinylsulfonyl, morpholinylmethyl, 4-methylpiperazinylmethyl, 4- methylpiperazinylpropyl, 4-isopropylpiperazinylmethyl, 4- methylpiperidinylmethyl, 4-aminopiperidinylmethyl, 4- methylamino-piperidinyl ethyl , 4-dimethylamino- piperidinylmethyl, 3-dimethylaminopyrrolidin-l-ylmethylmethyl
- the invention also relates to compounds of Formula II wherein R is substituted or unsubstituted 5-6 membered heterocyclyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R is substituted or unsubstituted 9-11 membered fused heterocyclyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R 1 is selected from unsubstituted or substituted 5- or 6-membered nitrogen-containing heteroaryl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R 1 is selected from unsubstituted or substituted phenyl; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein R 1 is selected from unsubstituted or substituted 9- or 10-membered nitrogen-containing partially saturated heterocyclyl and unsubstituted or substituted 9- or 10- membered nitrogen-containing heteroaryl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein W 1 and X are independently 0 or NH; wherein Y 2 is 0 or NH; wherein R is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 5-6 membered heterocyclyl , c) substituted or unsubstituted 9-13 membered fused heterocyclyl , and d) substituted or unsubstituted cycloalkyl, wherein substituted R is substituted with one or more substituents independently selected from halo, -OR 3 , -SR 3 , -C0 2 R 3 , -C(0)NR 3 R 3 , -C(0)R 3 , -NR 3 R 3 , -S0 2 R 3 , - S0 2 NR 3 R 3 , -NR 3 C(0)OR 3 , -NR 3 C(0)R 3 , -NR 3 C (0)NR 3 R 3
- R 1 is not 5- ( (2-chloro-6-methylphenyl) - aminocarbonyl) thiazol-2-yl when Y 2 is NH, W is NH and X is NH; further provided R 1 is not 2- (substituted aminocarbonyl) pyrid-4-yl when Y 2 is NH; further provided R 1 is not 2- (substituted aminocarbonyl)pyrid-4-yl when Y 2 is 0 and when R is phenyl or substituted
- the invention also relates to compounds of Formula II wherein R is a substituted or unsubstituted ring selected from phenyl, indanyl, tetrahydronaphthyl, naphthyl, cyclohexyl , indazolyl , indolyl , 2,1,3-benzothiadiazolyl , isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 2-oxo-l, 2-dihydroquinol- 7-yl, 1-oxo-l, 2 , 3 , 4-tetrahydro-isoquinolyl, 2 , 3-dihydro-l, 1- dioxo-benzo [d] isothiazolyl, isoindolyl, 2 , 3-dihydro-lH- indolyl, naphthy
- R x is selected from bromo, chloro, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl , 1, 1-di (trifluoromethyl) - 1-hydroxymethyl, trifluoromethoxy, difluoromethoxy, isopropoxy, methoxy and ethoxy; and wherein R y is selected from H, 4-methylpiperazinylsulfonyl, trifluoromethyl, morpholinylmethyl, 4-methylpiperazinylmethyl, 3- dimethylaminopyrrolidin-1-ylmethyl , 4- methylpiperazinylpropyl, 4-isopropylpiperazinylmethyl, 4- methylpiperidinylmethyl , 4-aminopiperidinylmethyl, 4- methylamino-piperidinylmethyl, 4-dimethylamino- piperidinylmethyl ,
- R 1 is a substituted or unsubstituted ring selected from 4-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, phenyl, 6-indazolyl, 4-quinolyl, indolyl, isoindolyl, benzotriazolyl, benzo [1, 3] dioxolyl, pyrrolo [2, 3-d] pyrimidin- 4-yl, 2-oxo-1 , 3-dihydro-pyrrolo [2 , 3-d]pyridin-4-yl, pyrazolo [2, 3 ,b]pyridin-4-yl, imidazo [4, 5-b]pyridin-4-yl, pyrrolo [2, 3-b]pyridin-4-yl, 2 , 3-dihydrobenzofuryl, 2-oxo- 1, 2-dihydroquinol-7-yl, and 4-quinazolinyl; wherein substitute
- the invention also relates to compounds of Formula II wherein R 1 is selected from unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroaryl; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein R 1 is a substituted or unsubstituted ring selected from 6-indazolyl, 4-quinolyl, pyrrolo [2 , 3-d]pyrimidin-4-yl , 2-oxo-1, 3-dihydro-pyrrolo [2, 3-d]pyridin-4-yl, pyrazolo [2,3 ,b]pyridin-4-yl, imidazo [4, 5-b]pyridin-4-yl, pyrrolo [2, 3-b]pyridin-4-yl, 2-oxo-l, 2-dihydroquinol-7-yl, and 4-quinazolinyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R 1 is a substituted or unsubstituted pyrrolo [2,3- b]pyridin-4-yl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R 1 is a substituted or unsubstituted 4-quinolyl; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein R 1 is a substituted or unsubstituted 4-quinazolinyl; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula II wherein R 1 is a substituted or unsubstituted pyrrolo [2,3- d]pyrimidin-4-yl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula II wherein R 2 is H or Cl ; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula III
- R is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 5-6 membered heterocyclyl , c) substituted or unsubstituted 9-13 membered fused heterocyclyl, and d) substituted or unsubstituted cycloalkyl, wherein substituted R is substituted with one or more substituents independently selected from halo, -OR 3
- the invention also relates to compounds of Formula III wherein R is a substituted or unsubstituted ring selected from phenyl , indanyl , tetrahydronaphthyl , naphthyl , cyclohexyl, indazolyl, indolyl, 2 , 1, 3-benzothiadiazolyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 2-oxo-l, 2-dihydroquinol- 7-yl, 1-oxo-l, 2 , 3 , 4-tetrahydro-isoquinolyl, 2 , 3-dihydro-l, 1- dioxo-benzo [d] isothiazolyl, isoindolyl, 2 , 3-dihydro-lH- indolyl, naphth
- R x is selected from bromo, chloro, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl , 1, 1-di (trifluoromethyl) - 1-hydroxymethyl, trifluoromethoxy, difluoromethoxy, isopropoxy, methoxy and ethoxy; and wherein R y is selected from H, 4-methylpiperazinylsulfonyl, trifluoromethyl, morpholinylmethyl, 4-methylpiperazinylmethyl, 3- dimethylaminopyrrolidin-1-ylmethyl , 4- methylpiperazinylpropyl, 4-isopropylpiperazinylmethyl, 4- methylpiperidinylmethyl , 4-aminopiperidinylmethyl, 4- methylamino-piperidinylmethyl , 4-dimethylamino- piperidinylmethyl
- R l is a substituted or unsubstituted ring selected from 6-indazolyl, 4-quinolyl, indolyl, isoindolyl, benzotriazolyl, benzo [1, 3] dioxolyl, pyrrolo [2 , 3-d]pyrimidin- 4-yl, 2-oxo-l, 3-dihydro-pyrrolo [2, 3-d] pyridin-4-yl, pyrazolo [2 , 3 ,b]pyridin-4-yl, imidazo [4, 5-b]pyridin-4-yl, pyrrolo [2, 3-b]pyridin-4-yl, 2 , 3-dihydrobenzofuryl, 2-oxo- 1, 2-dihydroquinol-7-yl, and 4-quinazolinyl; wherein substituted R 1 is substituted with one or more substituents independently selected from chloro, fluoro, bromo, hydroxy,
- the invention also relates to compounds of Formula III wherein R la is a substituted or unsubstituted pyrrolo [2,3- b]pyridin-4-yl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula III wherein R la is a substituted or unsubstituted 4-quinolyl; in conjunction with any of the above or below embodiments.
- the invention also relates to compounds of Formula III wherein R la is a substituted or unsubstituted 4- quinazolinyl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of. Formula III wherein R la is a substituted or unsubstituted pyrrolo [2, 3- d]pyrimidin-4-yl; in conjunction with any of the above or below embodiments .
- the invention also relates to compounds of Formula III wherein R 2 is H or Cl ; in conjunction with any of the above or below embodiments .
- a family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically- acceptable derivatives thereof as follows:
- Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of angiogenesis related diseases .
- the compounds of the invention have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity.
- the compounds of the invention are useful in therapy as antineoplasia agents or to minimize deleterious effects of VEGF.
- neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer) , esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma) ; hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin' s lymphoma, hairy cell lymphoma and Burkett ' s lymphoma); hematopoietic tumors of myeloid lineage (including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia
- tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma and schwannomas
- other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma
- the compounds are useful for the treatment of neoplasia selected from lung cancer, colon cancer and breast cancer.
- the compounds also would be useful for treatment of ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; and disorders of the female reproductive system such as endometriosis .
- the compounds are also useful for the treatment of edema, and conditions of vascular hyperpermeability.
- the compounds of the invention are useful in therapy of proliferative diseases. These compounds can be used for the treatment of an inflammatory rheumatoid or rheumatic disease, especially of manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases, especially chronic polyarthritis including rheumatoid arthritis, juvenile arthritis or psoriasis arthropathy; paraneoplastic syndrome or tumor-induced inflammatory diseases, turbid effusions, collagenosis , such as systemic Lupus erythematosus, poly-myositis, dermato-myositis, systemic sclerodermia or mixed collagenosis; postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body) , seronegative spondylarthritis, such as spondylitis ankylosans; vasculitis, sarcoidosis, or arthrosis; or further any combinations thereof.
- synovial inflammation for example, synovitis, including any of the particular forms of synovitis, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced.
- synovial inflammation may for example, be consequential to or associated with disease, e.g. arthritis, e.g. osteoarthritis, rheumatoid arthritis or arthritis deformans .
- the present invention is further applicable to the systemic treatment of inflammation, e.g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths .
- Such inflammation may be, for example, be consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis .
- the present invention is further especially applicable to the treatment of inflammation, e.g. inflammatory disease or condition, of connective tissues including dermatomyositis and myositis.
- These compounds can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration.
- some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome)) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.
- thyroid hyperplasia especially Grave's disease
- cysts such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome)
- some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease.
- the compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. fibrosis, cirrhosis and carpal tunnel syndrome) .
- the compounds of the present invention are also useful in the treatment of ulcers including bacterial, fungal, Mooren ulcers and ulcerative colitis.
- the compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke, endometriosis, ovarian hyperstimulation syndrome, systemic lupus, sarcoidosis, synovitis, Crohn's disease, sickle cell anemia, Lyme disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, and inflammatory rheumatoid or rheumatic disease.
- viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke,
- the compounds are also useful in the reduction of subcutaneous fat and for the treatment of obesity.
- the compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, glaucoma, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.
- the compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease.
- the compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing' s sarcoma and osteosarcoma) , retinoblastoma, rhabdomyosarcomas , neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor- induced pleural or pericardial effusions, and malignant ascites.
- cancer related indications such as solid tumors, sarcomas (especially Ewing' s sarcoma and osteosarcoma) , retinoblastoma, rhabdomyosarcomas , neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor- induced pleural or pericardial effusions, and malignant ascites.
- the compounds of the present invention are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy.
- the compounds of this invention may also act as inhibitors of other protein kinases, e.g. tie-2, lck, src, fgf, cmet, ron, ckit and ret, and thus be effective in the treatment of diseases associated with other protein kinases.
- other protein kinases e.g. tie-2, lck, src, fgf, cmet, ron, ckit and ret.
- these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
- the compounds of the present invention include the pharmaceutically acceptable derivatives thereof .
- treatment includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals) .
- a “pharmaceutically-acceptable derivative” denotes any salt, ester of a compound of this invention, or any other compound which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to inhibit angiogenesis.
- neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.
- H denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydroxyl radical .
- alkyl is used, either alone or within other terms such as “haloalkyl” and “alkylamino” , it embraces linear or branched radicals having one to about twelve carbon atoms . More preferred alkyl radicals are “lower alkyl” radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl and the like. Even more preferred are lower alkyl radicals having one or two carbon atoms.
- alkylenyl embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl .
- lower alkyl substituted with R 2 does not include an acetal moiety.
- alkenyl embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twelve carbon atoms . More preferred alkenyl radicals are "lower alkenyl” radicals having two to about six carbon atoms. Most preferred lower alkenyl radicals are radicals having two to about four carbon atoms . Examples of alkenyl radicals include ethenyl, propenyl , allyl, propenyl, butenyl and 4-methylbutenyl .
- alkenyl and “lower alkenyl” embrace radicals having "cis” and “trans” orientations, or alternatively, "E” and "Z” orientations.
- alkynyl denotes linear or branched radicals having at least one carbon-carbon triple bond and having two to about twelve carbon atoms . More preferred alkynyl radicals are "lower alkynyl” radicals having two to about six carbon atoms . Most preferred are lower alkynyl radicals having two to about four carbon atoms . Examples of such radicals include propargyl, butynyl, and the like.
- halo means halogens such as fluorine, chlorine, bromine or iodine atoms.
- haloalkyl embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl , dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl .
- a monohaloalkyl radical for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical.
- Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
- “Lower haloalkyl” embraces radicals having 1-6 carbon atoms.
- haloalkyl radicals having one to three carbon atoms.
- haloalkyl radicals include fluoromethyl , difluoromethyl, trifluoromethyl, chloromethyl , dichloromethyl , trichloromethyl, pentafluoroethyl , heptafluoropropyl , difluorochloromethyl, dichlorofluoromethyl , difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl .
- Perfluoroalkyl means alkyl radicals having all hydrogen atoms replaced with fluoro atoms .
- hydroxyalkyl embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl . Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms .
- alkoxy embrace linear or branched oxy- containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and terfc-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms . Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms .
- radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
- aryl alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner.
- aryl embraces aromatic radicals such as phenyl , naphthyl , indenyl , tetrahydronaphthyl , and indanyl . More preferred aryl is phenyl.
- Said "aryl” group may have 1 to 3 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino. Phenyl substituted with -0-CH 2 -0- forms the aryl benzodioxolyl substituent.
- heterocyclyl embraces saturated, partially saturated and unsaturated heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -0-0-,-0-S- or -S-S- portions.
- Said "heterocyclyl” group may have 1 to 3 substituents such as hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, amino and lower alkylamino.
- saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl] ; saturated 3 to 6- membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl] ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl] .
- nitrogen atoms e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl
- saturated 3 to 6- membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms e.g. morpholinyl
- heterocyclyl radicals examples include dihydrothienyl, dihydropyranyl , dihydrofuryl and dihydrothiazolyl .
- unsaturated heterocyclic radicals also termed "heteroaryl" radicals, include unsaturated 5 to 6 membered hetero onocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1, 2 , 4-triazolyl, 1H-1,2,3- triazolyl, 2H-1, 2 , 3-triazolyl] ; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl , 2-furyl, 3-furyl, etc.; unsaturated 5- to
- heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1, 5-b]pyridazinyl] ; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.
- heterocyclic radicals include ive to ten membered fused or unfused radicals .
- heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl.
- Other preferred heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.
- non-nitrogen containing heteroaryl include pyranyl, 2-furyl, 3-furyl, 2-thienyl, 3- thienyl, benzofuryl, benzothienyl, and the like.
- Particular examples of partially saturated and saturated heterocyclyl include pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl , thiazolidinyl, dihydrothienyl, 2 , 3-dihydro-benzo [1, 4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl , dihydrobenzofuryl, isochromanyl, chromanyl, 1, 2-dihydroquinolyl, 1,2,3,4- tetrahydro-isoquinolyl, 1,2,3, 4-tetrahydro-quinolyl, 2,3,4, 4a, 9 , 9a-hexahydro-lH-3-aza-fluorenyl, 5,6, 7-trihydro- 1,2, 4-triazolo [3 , 4-a] isoquinoly
- sulfonyl whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -S0 2 -.
- sulfamyl denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (-S0NH 2 ) .
- alkylaminosulfonyl includes "N- alkylaminosulfonyl” where sulfamyl radicals are independently substituted with one or two alkyl radical (s) . More preferred alkylaminosulfonyl radicals are “lower alkylaminosulfonyl” radicals having one to six carbon atoms. Even more preferred are lower alkylaminosulfonyl radicals having one to three carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, and N-ethylaminosulfonyl .
- carboxy or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl” , denotes -C0 2 H.
- N-alkylaminocarbonyl and N,N- dialkylaminocarbonyl denote aminocarbonyl radicals independently substituted with one or two alkyl radicals, respectively. More preferred are “lower alkylaminocarbonyl” having lower alkyl radicals as described above attached to an aminocarbonyl radical .
- N-arylaminocarbonyl and N-alkyl-N- arylaminocarbonyl denote aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical .
- heterocyclylalkylenyl embraces heterocyclic-substituted alkyl radicals.
- heterocyclylalkylenyl radicals are "5- or 6-membered heteroarylalkylenyl” radicals having alkyl portions of one to six carbon atoms and a 5- or 6-membered heteroaryl radical . Even more preferred are lower heteroarylalkylenyl radicals having alkyl portions of one to three carbon atoms . Examples include such radicals as pyridylmethyl and thienylmethyl .
- the term "aralkyl” embraces aryl-substituted alkyl radicals.
- Preferable aralkyl radicals are "lower aralkyl” radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms.
- phenylalkylenyl attached to alkyl portions having one to three carbon atoms.
- examples of such radicals include benzyl, diphenylmethyl and phenylethyl .
- the aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
- alkylthio embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower alkylthio radicals having one to three carbon atoms. An example of “alkylthio” is methylthio, (CH 3 S-) .
- haloalkylthio embraces radicals containing a haloalkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower haloalkylthio radicals having one to three carbon atoms . An example of "haloalkylthio" is trifluoromethylthio.
- alkylamino embraces “N-alkylamino” and "N,N-dialkylamino” where amino groups are independently substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are “lower alkylamino” radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms . Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.
- arylamino denotes amino groups which have been substituted with one or two aryl radicals, such as N- phenylamino.
- the arylamino radicals may be further substituted on the aryl ring portion of the radical.
- heteroarylamino denotes amino groups which have been substituted with one or two heteroaryl radicals, such as N-thienylamino .
- heteroarylamino radicals may be further substituted on the heteroaryl ring portion of the radical.
- aralkylamino denotes amino groups which have been substituted with one or two aralkyl radicals . More preferred are phenyl-C ⁇ -C 3 -alkylamino radicals, such as N-benzylamino . The aralkylamino radicals may be further substituted on the aryl ring portion.
- N-alkyl-N-arylamino and “N-aralkyl-N- alkylamino” denote amino groups which have been independently substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical, respectively, to an amino group .
- aminoalkyl embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals. More preferred aminoalkyl radicals are "lower aminoalkyl” radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl . Even more preferred are lower aminoalkyl radicals having one to three carbon atoms .
- alkylaminoalkyl embraces alkyl radicals substituted with alkylamino radicals.
- alkylaminoalkyl radicals are "lower alkylaminoalkyl” radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms .
- Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N-methylaminomethyl , N,N-dimethyl- aminoethyl, N,N-diethylaminomethyl and the like.
- alkylaminoalkoxy embraces alkoxy radicals substituted with alkylamino radicals.
- alkylaminoalkoxy radicals are "lower alkylaminoalkoxy" radicals having alkoxy radicals of one to six carbon atoms . Even more preferred are lower alkylaminoalkoxy radicals having alkyl radicals of one to three carbon atoms.
- alkylaminoalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminoethoxy, N,N- dimethylaminoethoxy, N,N-diethylaminoethoxy and the like.
- alkylaminoalkoxyalkoxy embraces alkoxy radicals substituted with alkylaminoalkoxy radicals. More preferred alkylaminoalkoxyalkoxy radicals are "lower alkylaminoalkoxyalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxyalkoxy radicals having alkyl radicals of one to three carbon atoms.
- Suitable alkylaminoalkoxyalkoxy radicals may be mono or dialkyl substituted, such as N- methylaminomethoxyethoxy, N-methylaminoethoxyethoxy, N,N- dimethylaminoethoxyethoxy, N,N-diethylaminomethoxymethoxy and the like.
- the term "carboxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more carboxy radicals. More preferred carboxyalkyl radicals are "lower carboxyalkyl" radicals having one to six carbon atoms and one carboxy radical. Examples of such radicals include carboxymethyl, carboxypropyl, and the like.
- halosulfonyl embraces sulfonyl radicals substituted with a halogen radical. Examples of such halosulfonyl radicals include chlorosulfonyl and fluorosulfonyl .
- arylthio embraces aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom.
- An example of “arylthio” is phenylthio.
- aralkylthio embraces aralkyl radicals as described above, attached to a divalent sulfur atom. More preferred are phenyl-C ⁇ -C 3 -alkylthio radicals. An example of “aralkylthio” is benzylthio.
- aryloxy embraces optionally substituted aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy.
- aralkoxy embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are "lower aralkoxy” radicals having optionally substituted phenyl radicals attached to lower alkoxy radical as described above.
- heteroaryloxy embraces optionally substituted heteroaryl radicals, as defined above, attached to an oxygen atom.
- heteroarylalkoxy embraces oxy-containing heteroarylalkyl radicals attached through an oxygen atom to other radicals . More preferred heteroarylalkoxy radicals are "lower heteroarylalkoxy” radicals having optionally substituted heteroaryl radicals attached to lower alkoxy radical as described above.
- cycloalkyl includes saturated carbocyclic groups .
- Preferred cycloalkyl groups include C 3 -C 6 rings . More preferred compounds include, cyclopentyl, cyclopropyl, and cyclohexyl .
- cycloalkenyl includes carbocyclic groups having one or more carbon-carbon double bonds including “cycloalkyldienyl” compounds.
- Preferred cycloalkenyl groups include C 3 -C 6 rings. More preferred compounds include, for example, cyclopentenyl, cyclopentadienyl, cyclohexenyl and eyeloheptadienyl .
- Formulas I-III includes any sub-formulas.
- the compounds of the invention are endowed with kinase inhibitory activity, such as KDR inhibitory activity.
- the present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously.
- the compounds of the present invention are useful in the manufacture of an anti-cancer medicament.
- the compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of KDR.
- the present invention comprises a pharmaceutical composition comprising a therapeutically-effective amount of a compound of Formulas I-III in association with a least one pharmaceutically-acceptable carrier, adjuvant or diluent.
- the present invention also comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I'
- W and X are independently selected from 0, S(0) n and NR 4 ; wherein Y 1 and Y 2 are independently selected from 0, S(0) n , N and NR 4 ; wherein ring A optionally contains a nitrogen atom independently at position 4, 6 or 7; wherein n is 0, 1 or 2 ; wherein R is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 5-6 membered heterocyclyl , c) substituted or unsubstituted 9-14 membered fused heterocyclyl, d) substituted or unsubstituted cycloalkyl, e) substituted or unsubstituted cycloalkenyl, and f) alkyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR 3 ,
- R 1 is selected from a) substituted or unsubstituted 6-10 membered aryl, b) substituted or unsubstituted 4-6 membered heterocyclyl , c) substituted or unsubstituted 9-14 membered fused heterocycl
- the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents .
- the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition.
- co-therapy in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co- administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
- the administration of compounds of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents.
- Such combination products employ the compounds of this invention within the accepted dosage ranges.
- Compounds of Formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.
- the invention is not limited in the sequence of administration; compounds of the invention may be administered either prior to, simultaneous with or after administration of the known anticancer or cytotoxic agent.
- the typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons.
- the chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.
- antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy.
- Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.
- a first family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents.
- Suitable antimetabolite antineoplastic agents may be selected from but not limited to the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba- Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co.
- EX-015 benzrabine, floxuridine, fludarabine phosphate, 5- fluorouracil, N- (2 ' -furanidyl) -5-fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC- 788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, Taiho UFT and uricytin.
- a second family of antineoplastic agents which may be used in combination with compounds of the present invention consists of alkylating-type antineoplastic agents.
- Suitable alkylating-type antineoplastic agents may be selected from but not limited to the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E
- a third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents.
- Suitable antibiotic-type antineoplastic agents may be selected from but not limited to the group consisting of Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-11, Ajinomoto AN- 3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol- Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin,
- a fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous family of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from but not limited to the group consisting of oc- carotene, ⁇ -difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2 , antineoplaston A3, antineoplaston A5 , antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-
- Org-10172 paclitaxel, pancratistatin, pazelliptine, Warner- Lambert PD-111707, Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976, SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP- 10094, spatol, spirocyclopropane derivatives, spirogermanium,
- the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos) , bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A) , daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docos,
- the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP) , COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics or ⁇ v ⁇ 3 inhibitors.
- other anti-neoplastic agents such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP) , COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics or ⁇ v ⁇ 3 inhibitors.
- the present invention comprises processes for the preparation of a compound of Formula I-III.
- compositions of Formula I-III are also included in the family of compounds of Formula I- III.
- pharmaceutically-acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
- Suitable pharmaceutically- acceptable acid addition salts of compounds of Formula I-III may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
- organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphoric, cam
- Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I-III include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, aistidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formula I-III .
- the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
- dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
- long chain halides such as de
- Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
- Preferred salts include hydrochloride, phosphate and edisylate.
- Substituted benzimidazoles can be prepared by the process outlined in Scheme 1.
- An benzimidazol-2-one can be prepared by the method described in J. Het., 2561 (1999), from the diamine 1.
- Treatment with P0C1 3 provides the 2- chloro compound 2, which can be substituted with a variety of compounds to form the benzimidazoles 3 of the present invention.
- substituted benzimidazoles 3 (where W is NH) can be prepared by the process outlined in Scheme 2.
- Diamine 1 is reacted with a substituted isothiocyanate 4, in an appropriate solvent such as CH 3 CN, at a temperature of about RT.
- Substituted amines can be prepared by the process outlined in Scheme 3.
- Substituted amines 6 can be prepared similar to that described in WO 03/006438. Reduction of the nitro substituted compound 6, such as with Pd/C and hydrogen, in the presence of an alcohol, such as EtOH, at a temperature about RT, provides the diamine 1.
- Substituted benzoxazoles can be prepared by the process outlined in Scheme 4.
- 1-Amino-2-hydroxy aromatic compounds 7 are reacted with a substituted isothiocyanate 4, in an appropriate solvent such as CH 3 CN, at a temperature of about RT.
- Azaindole phenol ethers can be prepared by the process outlined in Scheme 5.
- Halo substituted azaindoles 9 can be coupled with phenols and the like 10, such as in the presence of TFA:Et 3 N, at a temperature above about 50 °C, preferably above about 100 °C, and more preferably at about 150 °C, to form the protected ether 11.
- Reduction of the nitro substituted compound 13, such as with hydrogenation in the presence of a catalyst, such as Pd/C provides the amino substituted azaindole phenol ethers 1 .
- Substituted benzothiazoles can be prepared by the process outlined in Scheme 6.
- 2-Amino-5-hydroxy benzothiazoles 16 are reacted with a halo compound 15 to form the 2-amino-benzothiazole ether 17. Further substitution such as with substituted halides yields the disubstituted benzothiazole 18.
- substituted isothiocyanate 4 are reacted with l-amino-2-thio compounds 19 in an appropriate solvent such as CH 3 CN, at a temperature of about RT.
- substituted benzothiazoles can be prepared by the process outlined in Scheme 7. Substituted isothiocyanate are reacted with l-amino-2-thio compounds 20 in an appropriate solvent such as CH 3 CN, at a temperature of about RT. Addition of an amine coupling reagent, such as EDC, at a temperature above about 50 °C, and preferably at about 80 °C, forms the benzothiazoles 21. The 5-hydroxy benzothiazole 21 is reacted with a halo compound to form the 2-amino-benzothiazole ether 18.
- an amine coupling reagent such as EDC
- 4-Diaminophenyl ethers 25 are prepared by the method described in Scheme 8.
- 4-Dinitrophenyl ethers 24 are formed by coupling alcohols 22 with l-fluoro-3 , 4- dinitrobenzenes 23, in an appropriate solvent such as anhydrous DMF, and in the presence of base, such as KC0 3 , and at a temperature above about 50 °C, preferably above about 100 °C, more preferably at about 120 °C.
- Reduction of the nitro substituted compound 24, such as with hydrogenation in the presence of an alcohol, such as MeOH, in the presence of a catalyst, such as Pd/C provides the diamine 25.
- 2-Hydroxyanilines 29 are prepared by the method described in Scheme 9.
- Protected phenols 26 (were PG is a protecting group) are deprotected then nitrated to form the nitrophenols 28.
- the nitrophenols 28 are reduced to from the anilines 29.
- 4-Dinitrophenyl ethers 24 are prepared by the method described in Scheme 10.
- 4-Dinitrophenyl ethers 24 are formed by coupling compounds 30 where L is a leaving group such as halo, preferably chloro, with 3 , 4-dinitrophenols 31, at a temperature above about 50 °C, preferably above about 100 °C, more preferably at about 150 °C.
- the starting compounds defined in Schemes 1-10 may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt- forming group is present and the reaction in salt form is possible. If so desired, one compound of Formula I can be converted into another compound of Formula I or a N-oxide thereof; a compound of Formula I can be converted into a salt; a salt of a compound of Formula I can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of Formula I can be separated into the individual isomers.
- N-Oxides can be obtained in a known matter by reacting a compound of formula I with hydrogen peroxide, oxone, or a peracid, e.g.
- 3-chloroperoxy-benzoic acid in an inert solvent, e.g. dichloromethane, or a mixture of H 2 0 and an alcohol such as MeOH or EtOH, at a temperature between about -10-35 °C, such as about 0 °C - RT.
- an inert solvent e.g. dichloromethane, or a mixture of H 2 0 and an alcohol such as MeOH or EtOH
- one or more other functional groups for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formula I or in the preparation of compounds of Formula I, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars .
- the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
- the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.
- protecting groups are then wholly or partly removed according to one of the methods described there .
- Salts of a compound of Formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of Formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of Formula I) may also be converted into a salt with one acid molecule per compound
- a monohalogenide for example a monohalogenide
- this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from 130 to 170 °C, one molecule of the acid being expelled per molecule of a compound of Formula I .
- Salts can usually be converted to free compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
- suitable basic agents for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
- All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H + form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about - 100 °C to about 190 °C, preferably from about -80 °C to about 150 °C, for example at about -80 to about 60 °C, at room temperature, at about -20 to about 40 °C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen. Salts may be present in all starting compounds and transients, if these
- the solvents from which those can be selected which are suitable for the reaction in question include for example water, esters, typically lower alkyl-lower alkanoates, e.g., EtOAc, ethers, typically aliphatic ethers, e.g., Et 2 0, or cyclic ethers, e.g., THF, liquid aromatic hydrocarbons, typically benzene or iPrOH toluene, alcohols, typically MeOH, EtOH or 1-propanol, nitriles, typically CH 3 CN, halogenated hydrocarbons, typically CH 2 C1 2 , acid amides, typically DMF, bases, typically heterocyclic nitrogen bases, e.g.
- esters typically lower alkyl-lower alkanoates
- ethers typically aliphatic ethers, e.g., Et 2 0, or cyclic ethers, e.g., THF
- liquid aromatic hydrocarbons typically benzene or iPrOH toluen
- carboxylic acids typically lower alkanecarboxylic acids, e.g., AcOH
- carboxylic acid anhydrides typically lower alkane acid anhydrides, e.g., acetic anhydride
- cyclic linear, or branched hydrocarbons, typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e.g., aqueous solutions, unless otherwise stated in the description of the process .
- solvent mixtures may also be used in processing, for example in chromatography.
- the invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ .
- the compounds of Formula I are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates) .
- New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
- such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
- All remaining starting materials are known, capable of being prepared according to known processes, or commercially obtainable; in particular, they can be prepared using processes as described in the examples .
- Compounds of the present invention can possess, in general, one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof.
- the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e . g. , by formation of diastereoisomeric salts, by treatment with an optically active acid or base.
- Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
- a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
- Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate.
- the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound.
- the optically active compounds of the invention can likewise be obtained by using optically active starting materials . These isomers may be in the form of a free acid, a free base, an ester or a salt.
- the compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures . All such isomeric forms of these compounds are expressly included in the present invention.
- the compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:
- the invention expressly includes all tautomeric forms of the compounds described herein.
- the compounds may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
- Substituents on ring moieties may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom, whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen) .
- the compounds of this invention may contain heterocyclic ring systems attached to another ring system.
- Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system.
- a compound of any of the formulas delineated herein may be synthesized according to any of the processes delineated herein.
- the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary.
- the processes may further comprise use of appropriate reaction conditions, including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K 2 C0 3 , and the like), catalysts, and salt forms of the above.
- bases e.g., LDA, DIEA, pyridine, K 2 C0 3 , and the like
- Purification methods include, for example, crystallization, chromatography (liquid and gas phase, and the like) , extraction, distillation, trituration, reverse phase HPLC and the like. Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
- reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
- the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds.
- Synthetic chemistry transformations and protecting group methodologies useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 rd . Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994) ; A. Katritzky and A. Pozharski, Handbook of Heterocyclic Chemistry, 2 nd Ed. (2001) ; M.
- Bodanszky A. Bodanszky: The Practice of Peptide Synthesis Springer-Verlag, Berlin Heidelberg (1984); J. Seyden-Penne : Reductions by the Alumino- and Borohydrides in Organic Synthesis, 2 nd Ed. , Wiley-VCH, (1997); and L. Paquette (editor) , Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) .
- the compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- the mobile phase used solvent A (H 2 O/0.1% AcOH) and solvent B (CH 3 CN/0.1% AcOH) with a 10 min gradient from 10% to 90% CH 3 CN. The gradient was followed by a 1 min return to 10% CH 3 CN and a 2 min flush.
- Preparation VII 1-Methanesulfonyl-piperazine.
- l-Boc-4-Methanesulfonyl-piperazine (10.4 g, 39.5 mmol) was dissolved in 50 mL CH 2 Cl 2 and treated with 15 mL TFA. After stirring at RT for 18 h, the reaction was concentrated in vacuo, dissolved in 1 N HCI and extracted twice with CH 2 C1 2 . The aqueous layer was basified to pH>12 with solid NaOH, then extracted twice with EtOAc. The EtOAc layer was washed with a mix of brine and 1 N NaOH, dried over Na 2 S0 4 , filtered, and concentrated in vacuo, to yield the title compound as a clear liquid.
- MS (MH + ) NA; Calc'd 164.23 for C 5 H 12 N 2 0 2 S.
- the acidic aqueous layer was basified with NaOH pellets and extracted 4x with CH 2 C1 2 .
- the CH 2 Cl 2 layers were combined, dried over Na 2 S0 , filtered, and concentrated in vacuo.
- the residue was purified by silica gel column chromatography to yield the title compound.
- the crude residue was treated with a small mix of Et 2 0 and hexanes and sonicated so as to triturate out bulk of impurities, which were filtered off. The filtrate was concentrated to dryness. The resulting residue was purified by silica gel column chromatography using 7% EtOAc in hexanes to elute the title compound as a thick yellow oil .
- the combined acidic aqueous layers were basified to pH>12 with solid NaOH and extracted 3x with EtOAc.
- the EtOAc layers were washed once with 2 N NaOH then once with a mixture of brine and 2 N NaOH, combined, dried over Na 2 S0 4 , filtered, and concentrated down to dryness, to yield the title compound.
- the combined acidic aqueous layers were basified to pH > 12 with solid NaOH and extracted 3x with EtOAc.
- the EtOAc layers were washed once with 2 N NaOH and then once with mix of brine and 2 N NaOH, combined, dried over Na 2 S0, filtered, and concentrated to dryness, to yield the title compound.
- Step A 4- (3,4-Dinitrophenoxy)pyridine-2-carboxylic acid methylamide.
- Step B 4- (3,4-Diamino-phenoxy) -pyridine-2-carboxylic acid methylamide.
- Step A 4- (3 , 4-Dinitro-phenoxy) -pyridine-2-carboxylic acid methylamide (Step A) (0.71 g, 2.23 mmol) was dissolved in 40 mL MeOH and 80 mL EtOAc. To the argon-degassed solution was added 10% Pd/C (0.20 g) . The reaction was vigorously stirred for 42 h at RT under 1 atm of H 2 gas . The reaction was filtered through a Celite ® plug. The solvent was removed under reduced pressure to obtain the title compound.
- Step C 4- [2- (4-Chloro-3-trifluoromethyl-phenylamino) -12T- benzimidazol-5-yloxy] -pyridine-2-carboxylic acid methylamide .
- Step B To a solution of 4- (3 , 4-diamino-phenoxy) -pyridine-2- carboxylic acid methylamide (Step B) (0.07 g, 0.27 mmol) in 20 mL CH 3 CN was added dropwise, over 5 min, a solution 1- chloro-4-isothiocyanato-2-trifluoromethyl-benzene (0.055 g, 0.27 mmol) in 10 mL CH 3 CN. The reaction was stirred 18 h at RT. The reaction was diluted with 10 mL CH 3 CN, then EDC (0.078 g, 0.41 mmol) was added. The reaction was heated at 80 °C for 3 h. The reaction was cooled to RT and concentrated in vacuo .
- Step A 1- [2- (5-Nitro-2-pentafluoroethylphenoxy) -ethyl] - pyrrolidine .
- Step B 4-Pentafluoroethyl-3- (2-pyrrolidin-1-yl-ethoxy) - phenylamine.
- Step A 1- [- (5-nitro-2- pentafluoroethyl-phenoxy) -ethyl] -pyrrolidine (Step A) (1.8 g) and MeOH (25 mL) and placed under argon. Pd/C was added carefully and the atmosphere was replaced with H 2 . The reaction was stirred for 2.5 days at RT. The reaction mixture was blanketed with N 2 , filtered through a pad of Celite ® and evaporated. The reaction mixture was taken up in a small amount of acetone, and filtered through a plug of silica gel using 90:10:1 (CH 2 C1 2 :MeOH:NH 4 OH) as the eluant. The title compound was isolated as a yellow solid.
- Step C 4- ⁇ 2-[4-Pentafluoroethyl-3-(2-pyrrolidin-l-yl- ethoxy) -phenylamino] -lH-benzimidazol-5-oloxy ⁇ -pyridine-2- carboxylic acid methylamide.
- Step A 3-Nitro-5-trifluoromethyl-phenol.
- l-Methoxy-3-nitro-5-trifluoromethyl-benzene (10 g, Aldrich) and pyridine-HCl (41.8 g, Aldrich) were mixed together and heated neat at 210 °C in an open flask. After 2.5 h, the mixture was cooled to RT and partitioned between IN HCl and EtOAc. The EtOAc fraction was washed with 1 N HCl (4x) , brine (lx) , dried with Na 2 S0 , filtered and concentrated in vacuo to form 3-nitro-5-trifluoromethyl- phenol as an off-white solid.
- Step B 1- [2- (3-Nitro-5-trifluoromethyl-phenoxy) ethyl] - pyrrolidine.
- Step C 3-(2-Pyrrolin-l-yl-ethoxy)-5-trifluoromethyl- phenylamine.
- Step D 1- [2- (3-Thioisocyanato-5-trifluoromethyl-phenoxy) - ethyl] -pyrrolidine.
- Step E 4- ⁇ 2-[3-(2-Pyrrolidin-l-yl-ethoxy)-5- trifluoromethyl-phenylamino] -lH-benzimidazol-5-yloxy ⁇ - pyridine-2-carboxylic acid methylamide.
- 3-Methoxy-l-nitro-4- (perfluoroethyl) benzene can be synthesized by the method similar to that described in J. Freskos, Synthetic Communications , 18 (9) : 965-972 (1988).
- 3-methoxy-l-nitro-4- (perfluoroalkyl) benzene can be synthesized from a p-iodonitrobenzene compound by the method described by W. Gregory, et al . [J. Med. Chem., 33:2569-2578 (1990) ] .
- Step C 2?-2-(5-Nitro-2-pentafluoroethyl-phenoxymethyl) -1- ( ert-butoxycarbonyl)pyrrolidine.
- Step D R-2- (5-Amino-2-pentafluoroethyl-phenoxymethyl) - 1- ( ert-butoxycarbonyl)pyrrolidine.
- Step F J?-2- ⁇ 5- [5- (2-Methylcarbamoyl-pyridin-4-yloxy) -1H- benzimidazol-2-ylamino] -2-pentafluoroethyl-phenoxymethyl ⁇ -1- ( ert-butoxycarbonyl)pyrrolidine.
- Step G 4- ⁇ 2-K- [4-Pentafluoro-3- (pyrrolidin-2-ylmethoxy) - phenylamino] -lff-benzimidazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methylamide.
- Step A R-2- (5-Nitro-2-pentafluoroethyl-phenoxymethyl) - pyrrolidine.
- Step B JS-1-Methyl-2- (5-nitro-2-pentafluoroethyl- phenoxymethyl) -pyrrolidine.
- Step C .R-l-Methyl-2- (5-amino-2-pentafluoroethyl- phenoxymethyl) -pyrrolidine.
- Step D ⁇ -4- ⁇ 2-[3-(l-Methyl-pyrrolidin-2-ylmethoxy)-4- pentafluoroethyl-phenylamino] -lH-benzimidazol-5-yloxy ⁇ - pyridine-2-carboxylic acid methylamide.
- Step B 2- (2-Methoxy-5-nitrophenyl) acetic acid.
- Step A The crude (2-methoxy-5-nitrophenyl) -acetonitrile (Step A) was stirred, heated with 20 mL of 12 M HCl at reflux for 3 h, then at 60 °C overnight. After cooling, the product was extracted in CHC1 2 (3 x 40 mL) , washed with water then extracted into 3 M NaOH. The basic extracts were washed with CH 2 C1 2 , acidified (6 M HCl) and the solid was collected, washed well with water and dried in air giving pure 2- (2-methoxy-5-nitrophenyl) acetic acid.
- Step C 2- (2-Methoxy-5-nitrophenyl) -N,N-dimethyl-acetamide.
- Step D [2- (2-Methoxy-5-nitrophenyl) -ethyl] -dimethyl-amine .
- Step E 3- (2-Dimethylamino-ethyl) - -methoxy-phenylamine .
- Step F 4- ⁇ 2- [3- (2-Dimethylamino-ethyl) -4-methoxy- phenylamino] -lH-benzimidazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methylamide
- MS (MH + ) 461.1, MW: 460.21 Calc'd for: C 25 H 28 N 6 0 3 .
- Step A l-Bromo-2-difluoromethoxy-4-nitro-benzene.
- Step B 1- (2-Difluoromethoxy-4-nitro-phenyl) -4-isopropyl- piperazine.
- l-Bromo-2-difluoromethoxy-4-nitro-benzene (Step A, 2.0 g, 7.5 mmol, 1.0 eq.) and N- (2-propyl )piperazine (0.85 mL, 9.7 mmol, 1.3 eq.) were dissolved in 20 mL of DMSO.
- K 2 C0 3 1.5 g, 11.2 mmol, 1.5 eq.
- BuN + Br " 240 mg, 0.75 mmol, 0.1 eq.
- Step C 3-Difluoromethoxy-4- (4-isopropyl-piperazin-l-yl) - phenylamine .
- Step D 4- ⁇ 2- [3-Difluoromethoxy-4- (4-isopropyl-piperazin-l- yl) -phenylamino] -lH-benzimidazol-5-yloxy ⁇ -pyridine-2- carboxylic acid methylamide.
- Step A 5-Nitro-2-t-butylaniline.
- Step C N-(2-tert-Butyl-5-nitro-phenyl) -2-dimethylamino- acetamide.
- Step D N- (5-Amino-2-tert-butyl-phenyl) -2-dimethylamino- acetamide.
- N- (2-tert-Butyl-5-nitro-phenyl) -2-dimethylamino- acetamide 25.8 g, 92 mmol was dissolved into EtOH (1.4 liters) and 1,4-dioxane (200 mL) . The solution was degassed under vacuum with stirring. 10% Pd/C (2.5 g) was added (as a slurry in EtOH) . The mixture was degassed again, then the reaction vessel was charged with H 2 gas (balloon) and stirred overnight at RT.
- Step E 4- ⁇ 2- [4-tert-Butyl-3- (2-dimethylamino-acetylamino) - phenylamino] -lH-benzimidazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methylamide.
- Step B l-Methyl-4- [1-methyl-l- (4-nitro-phenyl) -ethyl] - 1,2,3, 6-tetrahydro-pyridine .
- l-Methyl-4- [1-methyl-l- (4-nitro-phenyl) -ethyl] - pyridinium was treated with DEA (100 mL) in MeOH
- Step C 4- [1-Methyl-l- (1-methyl-piperidin- -yl) -ethyl]- phenylamine .
- l-Methyl-4- [1-methyl-l- (4-nitro-phenyl) -ethyl] - 1,2 , 3, 6-tetrahydro-pyridine (Step B) was hydrogenated with Pd/C 10% at atmospheric pressure at RT in EtOH to yield the title compound.
- Step D 4-(2- ⁇ 4-[l-Methyl-l-(l-methyl-piperidin-4-yl)- ethyl] -phenylamino ⁇ -lH-benzimidazol-5-yloxy) -pyridine-2- carboxylic acid methylamide.
- Step A (2-Chloro-5-nitro-benzyl) - (2-methyl-allyl) -amine.
- Step B N-Boc-(2-Chloro-5-nitro-benzyl)-(2-methyl-allyl)- amine.
- Step C 2-Boc-4,4-dimethyl-7-nitro-3,4-dihydro-2H- isoquinoline.
- Step B To a solution of the residue Step B (10 g) in DMF (100 mL) was added Pd(OAc) 2 (0.6 g) , sodium formate (2.2 g) , NaOAc (6.1 g) and tetraethylammonium hydrate (5.4 g). N 2 was bubbled (under surface) through the mixture for 30 min. The mixture was heated to 83 - 85 °C for 4.5 h. The mixture was cooled to ⁇ 25 °C and filtered through Celite ® bed. The Celite ® bed was washed with water (300 mL) and EtOAc (200 mL) . The organic phase was separated.
- Step D 2-Boc-4,4-dimethyl-7-amino-3,4-dihydro-2H- isoquinoline .
- Step C To the organic phase (Step C) was added 10% Pd/C (wet) (1.2 g) . H 2 (1 atm) was applied. The mixture was stirred overnight. The mixture was filtered through Celite ® bed. The bed was washed with EtOAc (50 mL) . The solvent was removed under reduced pressure to give an oil residue that solidified upon standing.
- Step E 2-tert-Butoxycarbonyl-4,4-Dimethyl-7- [5- (2- methylcarbamoyl-pyridin-4-yloxy) -lH-benzimidazol-2-ylamino] - 3,4-dihydro-lH-isoquinoline.
- MS (MH + ) 543.30; Calc'd 542.26 for C 30 H 34 N s O 4 .
- Step A 4- ⁇ 2-Chloro-5- [5- (2-methylcarbamoyl-pyridin-4- yloxy) -lH-benzimidazol-2-ylamino] -benzyl ⁇ -piperazino-l- carboxylic acid tert-butyl ester
- Step B 4- [2- (4-Chloro-3-piperazin-l-ylmethyl-phenylamino) - lH-benzimidazol-5-yloxy] -pyridine-2-carboxylic acid methylamide
- Step B 3- (4-Amino-3-nitro-phenoxy) -.V-methyl-benzamide
- Step C 3- (3,4-Diamino-phenoxy) -lV-methyl-benzamide
- Step D 3- ⁇ 2- [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) - phenylamino] -lH-benzimidazol-5-yloxy ⁇ --V-methyl-benzamide .
- Step A _V- [3- (3,4-Dinitro-phenoxy) -phenyl] -acetamide
- Step B N- [3- (3,4-Diamino-phenoxy) -phenyl] -acetamide.
- Step C N- (3- ⁇ 2- [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) - phenylamino] -lH-benzimidazol-5-yloxy ⁇ -phenyl) -acetamide .
- Step B 4- (4,5-Dinitro-2-methyl-phenoxy) -pyridine-2- carboxylic acid methylamide.
- Step C 4- (4, 5-Diamino-2-methyl-phenoxy) -pyridine-2- carboxylic acid methylamide
- Step D 4- [2- (4-Chloro-3-trifluoromethyl-phenylamino) -6- methyl-lH-benzimidazol-5-yloxy] -pyridine-2-carboxylic acid methylamide
- Step A 3- (4-Amino-3-nitro-phenoxy) -.V-methyl-benzamide.
- Step B 4-(4-methylamino-3-nitrophenoxy)-pyridine-2- carboxylic acid methylamide.
- Step C 3- (3-Amino-4-methylamino-phenoxy) -lV-methyl-benzamide
- Step D 4- ⁇ 2- [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) - phenylamino] -l-methyl-lH-benzimidazol-5-yloxy ⁇ -pyridine-2- carboxylic acid methylamide
- Step A 4- (3,4-Dinitro-phenoxy) -2-methylsulfanyl-pyrimidine.
- Step B 4- (2-Methylsulfanyl-pyrimidin-4-yloxy) -benzene-1,2- diamine.
- Step A 4- (3 , 4-Dinitro-phenoxy) -2-methylsulfanyl-pyrimidine (Step A, 1.0 g, 3.2 mmol, 1.0 eq.) was dissolved in MeOH (10 mL) and the atmosphere was replaced by argon. A catalytic amount of 10% Pd/C was added and the argon was replaced by a H 2 atmosphere . The mixture was hydrogenated for 2 h at RT at 60 psi using a Parr hydrogenation apparatus. More Pd/C was added and the mixture was hydrogenated for another 4 h at 60 psi. The Pd/C was removed by filtration. The crude aniline was purified using column chromatography (0-100% EtOAc in hexanes) to give 4- (2-methylsulfanyl-pyrimidin-4- yloxy) -benzene-1 , 2-diamine .
- Step C [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) -phenyl] - [5- (2-methylsulfanyl-pyrimidin-4-yloxy) -lH-benzimidazol-2- yl] -amine.
- the resulting mixture was heated to 80 °C for 1 h.
- the solvent was evaporated and the residue was diluted with CH 2 C1 2 (25 mL) .
- the solution was washed with H 2 0 (25 mL) , NaHC0 3 (25 mL, aq.) and brine (25 mL) .
- the aqueous layers were back extracted with CH 2 C1 2 and the combined organic layers were dried over MgS0 4 , filtered and concentrated.
- Step A (4-Chloro-3-trifluoromethyl-phenyl) - [5- (2- methylsulfanyl-pyrimidin-4-yloxy) -lH-benzimidazol-2-yl] - amine.
- Step B (4-Chloro-3-trifluoromethylphenyl) - [5- (2- methylsulfonylpyrimidin-4-yloxy) -lff-benzimidazol-2-yl] - amine.
- Step C (4-Chloro-3-trifluoromethyl-phenyl) - [5- (2- methylamino-pyrimidin-4-yloxy) -lH-benzimidazol-2-yl] -amine .
- Step B 120 mg, 0.2 mmol, 1.0 eq.
- anhydrous THF 4 mL
- Step A 4- (3, -Dinitro-phenoxy) -2-methylsulfonyl-pyrimidine .
- Step B 4- (2- Methylsulfonyl-pyrimidin-4-yloxy) -benzene-1, 2- diamine.
- Step A 4- (3 , 4-Dinitro-phenoxy) -2-methylsulfonyl-pyrimidine (Step A, 1.0 g, 2.9 mmol, 1.0 eq.) was dissolved in MeOH (50 mL) and the atmosphere was replaced by argon. A catalytic amount of 10% Pd/C was added and the argon was replaced by a H 2 atmosphere. The mixture was stirred for 16 h at RT at atmospheric pressure. More Pd/C was added after the atmosphere was replaced by argon, then the reaction was stirred under H 2 at RT for 48 h.
- Step C 4- (2-Methylamino-pyrimidin-4-yloxy) -benzene-1, 2- diamine.
- Step D [4-Chloro-3- (4-methylpiperazin-l-ylmethyl)phenyl] - [5- (2-methylamino-pyrimidin-4-yloxy) -lH-benzimidazol-2-yl] - amine
- Step C 4- (3,4-Dinitro-phenoxy) -lH-pyrrolo[2,3-b]pyridine.
- Step D 4-(lH-Pyrrolo[2,3-b]pyridin-4-yloxy) -benzene-1,2- diamine .
- Step E (4-Chloro-3-trifluoromethyl-phenyl)- [6- (1H- pyrrolo[2,3-b]pyridin-4-yloxy) -lH-benzimidazol-2-yl] -amine.
- Step A 4- (3,4-Dinitro-phenoxy) -7,7a-dihydro-4aH- pyrrolo [2, 3-d]pyrimidine .
- Step B [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) -phenyl] - [6- (7H-pyrrolo[2,3-d]pyrimidin-4-yloxy) -lH-benzimidazol-2- yl] -amine.
- Step A 4- (3,4-Dinitro-phenoxy) -quinoline.
- Step B 4- (Quinolin-4-yloxy) -benzene-1,2-diamine.
- Step A 4- (3 , 4-Dinitro-phenoxy) -quinoline (Step A, 400 mg, 1.2 mmol) was dissolved in THF at 0 °C, and AcOH (1.5 mL) was added followed by zinc dust (2.5 g, 38 mmol) . The mixture was stirred at RT for 1 h then filtered on a silica pad. The solvent was evaporated; the residue was dissolved in CH 2 C1 2 and washed with IM NaOH. The organic phases were dried, filtered and evaporated to give the title compound, as a brown-orange oil .
- Step C [5- (Quinolin-4-yloxy) -lH-benzimidazol-2-yl] -(4- trifluoromethyl-phenyl) -amine .
- 4- (quinolin-4-yloxy) -benzene-1, 2- diamine (Step B, 227 mg) in CH 3 CN (60 mL) was added over 5 min, a solution of l-isothiocyanato-4-trifluoromethyl- benzene (183 mg) in CH 3 CN 10 mL) .
- the mixture was stirred for 12 h at RT and EDC (260 mg) was added, followed by CH 3 CN (30 mL) .
- Step A 4- (4-Benzyloxy-phenoxy) -2-chloro-pyrimidine.
- Step B [4- (4-Benzyloxy-phenoxy) -pyrimidin-2-yl] -methyl- amine.
- Step A 4- (4-Benzyloxy-phenoxy) -2-chloro-pyrimidine (Step A, 2.03 g, 6.49 mmol) was dissolved in 10 mL DMSO in a sealed tube at 0 °C. 2 N CH 3 NH 2 (in THF) was added (4.9 mL, 9.7 mmol) , and the tube was sealed, warmed first to RT for 2 h, then to 70 °C for 2 h with stirring. The reaction was cooled to RT and concentrated in vacuo to a DMSO solution. The crude solution was diluted into Et 2 0 and IN NaOH (aq) was added. The layers were separated, and the organic layer was washed several times with water then brine.
- Step C 4- (2-Methylamino-pyrimidin-4-yloxy) -phenol.
- Step D 4 -(2-Methylamino-pyrimidin-4-yloxy) -2-nitro-phenol.
- Step E 2-Amino-4- (2-methylamino-pyrimidin-4-yloxy) -phenol .
- Step F [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) -phenyl] - [5- (2-methylamino-pyridin-4-yloxy) -benzoxazol-2-yl] -amine.
- Step B 4- ⁇ 2-[4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) - phenylamino] -benzoxazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methylamide.
- Step A 2-Nitro-4- (quinolin-4-yloxy) -phenol.
- Step B 2-Amino-4- (quinolin-4-yloxy) -phenol .
- Step C ( [4-Chloro-3- (4-methyl-piperazin-l-ylmethyl) - phenyl] - [5- (quinolin-4-yloxy) -benzoxazol-2-yl] -amine)
- Step B N 5 - (4-Quinolinyl) -N 2 - (4- (trifluoromethyDphenyl) - 1,3-benzoxazole-2, 5-diamine.
- Step A 6, 7-Dimethoxy-4-hydroxyquinoline (Step A, 7.8 g) was dissolved in P0C1 3 (45 mL) and heated at 85 °C for 3 h. The mixture was cooled down to RT, P0C1 3 was evaporated and the resulting oil was quenched by adding ice at 0 °C. The aqueous phase was basified to pH 8 and a solid precipitated. The solid was filtered and dried under vacuum to give 4- chloro-6 , 7-dimethoxyquinoline .
- Step C 5- ( (6, 7-bis (Methoxy) -4-quinolinyl) oxy) -N- (4-chloro- 3- ( (4-methyl-l-piperazinyl)methyl)phenyl) -l,3-benzoxazol-2- amine
- Step A 4- (4-Benzyloxy-phenoxy) -lH-pyrrolo [2,3-b]pyridine
- Step B N-(4-Chloro-3-( (4-methyl-l- piperazinyl)methyl) henyl) -5- (lH-pyrrolo[2,3-b]pyridin-4- yloxy)-l,3-benzoxazol-2-amine.
- Step A l-Chloro-2- (2-methoxyethoxy) -4-nitrobenzene
- Step C N-(4-Chloro-3-( (2- (methoxy)ethyl)oxy)phenyl) -5- (4- quinolinyloxy) -1,3-benzoxazol-2-amine
- Step A 4- (3, -Dinitrophenoxy) -6,7-dimethoxyquinoline
- Step B 4- (6,7-Dimethoxyquinolin-4-yloxy) -benzene-1,2- diamine
- Step a 4- (3 , 4-Dinitrophenoxy) -6, 7-dimethoxyquinoline (Step a, 0.256 g) was dissolved in THF (40 mL) and HOAc (1 mL) was added followed by zinc dust (1.3 g) . Mixture was stirred at RT for 3 h and filtered through a Celite ® pad. Solvent was evaporated and residue was washed with NaOH 1 M and extracted with EtOAc. The organic phase was dried, filtered and evaporated to give the title compound.
- Step C [4-Chloro-3- (4-methylpiperazin-l-ylmethyl) -phenyl] [5- (6,7-dimethoxyquinolin-4-yloxy) -lH-benzimidazol-2-yl] - amine
- Step A 4- (6,7-Dimethoxyquinazolin-4-yloxy) -2-nitro- phenylamine
- DMSO 3.8 ml, 5X
- KOt-Bu 0.6 g, 5.34 mmol, 1.2 eq
- the contents were treated with 4-chloro-6, 7- dimethoxyquinazoline (1.0 g, 4.45 mmol, i.O eq) and K 2 C0 3 (0.33 g, 2.4 mmol, 0.53 eq) then heated at 110 °C for 16 h.
- Step A 4- (6, 7-Dimethoxyquinazolin-4-yloxy) -2-nitro- phenylamine (Step A, 1 g, 2.9 mmol) was dissolved in EtOH (200 mL) and glacial acetic acid (10 mL) and placed under nitrogen. Pd/C was added, the reaction mixture blanketed with H 2 , the mixture was shaken under H 2 for 18 h at 55 psi. The catalyst was removed by filtration through Celite ® and the solution was concentrated in vacuo . The residue was dissolved in MeOH/H 2 0 and NHOH was added to adjust to PH
- Step C (4-Chloro-phenyl)- [5- (6,7-dimethoxy-quinazolin-4- yloxy) -lH-benzoimidazol-2-yl] -amine
- Step A 4- (4-Benzyloxy-phenoxy) -2-chloro-pyridine
- Step B [4- (4-Benzyloxy-phenoxy) -pyridin-2-yl] -methylamine
- the reaction was heated to 100 °C for 7 days. During that period, an additional amount of CH 3 NH 2 solution was added on four separate days (for a total of 70 mL) .
- the reaction was cooled to RT and diluted into IN NaOH and Et 2 0 after evaporating off THF. After separation of the layers, the organic layer was washed 3x with IN NaOH then with brine. The crude residue was eluted on a silica gel column with a hexanes/EtOAc gradient to yield the title compound.
- Step C 4- (2-Methylamino-pyridin-4-yloxy) -phenol
- Step D 4- (2-Hethylamino-pyridin-4-yloxy) -2-nitrophenol
- Step F [4-Chloro-3- ( (2S) -l-methyl-pyrrolidin-2-ylmethoxy) - phenyl] - [5- (2-methyl-amino-pyridin-4-yloxy) -benzoxazol-2- yl] -amine
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05010086A MXPA05010086A (en) | 2003-03-21 | 2004-03-22 | Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors. |
EP04758050A EP1638954A1 (en) | 2003-03-21 | 2004-03-22 | Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors |
CA002518909A CA2518909A1 (en) | 2003-03-21 | 2004-03-22 | Heterocyclic compounds and methods of use |
JP2006507472A JP2006520805A (en) | 2003-03-21 | 2004-03-22 | Heterocyclic compounds and methods of use thereof |
AU2004223827A AU2004223827B2 (en) | 2003-03-21 | 2004-03-22 | Heterocyclic compounds and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45669103P | 2003-03-21 | 2003-03-21 | |
US60/456,691 | 2003-03-21 | ||
US10/804,915 | 2004-03-19 | ||
US10/804,915 US7531553B2 (en) | 2003-03-21 | 2004-03-19 | Heterocyclic compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004085425A1 true WO2004085425A1 (en) | 2004-10-07 |
Family
ID=33101264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/008809 WO2004085425A1 (en) | 2003-03-21 | 2004-03-22 | Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors |
Country Status (7)
Country | Link |
---|---|
US (1) | US7531553B2 (en) |
EP (1) | EP1638954A1 (en) |
JP (1) | JP2006520805A (en) |
AU (1) | AU2004223827B2 (en) |
CA (1) | CA2518909A1 (en) |
MX (1) | MXPA05010086A (en) |
WO (1) | WO2004085425A1 (en) |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087153A3 (en) * | 2003-03-28 | 2005-03-17 | Chiron Corp | Use of organic compounds for immunopotentiation |
WO2005032548A1 (en) * | 2003-09-29 | 2005-04-14 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
WO2005042520A1 (en) * | 2003-10-24 | 2005-05-12 | Merck Patent Gmbh | Benzimidazolyl derivatives |
WO2005073224A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
EP1674466A1 (en) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
WO2007095124A3 (en) * | 2006-02-10 | 2007-11-01 | Transtech Pharma Inc | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
JP2008517890A (en) * | 2004-10-22 | 2008-05-29 | キャンサー・リサーチ・テクノロジー・リミテッド | Imidazo [4,5-B] pyridin-2-one and oxazolo [4,5-B] pyridin-2-one compounds and their analogs as therapeutic compounds |
JP2008524282A (en) * | 2004-12-22 | 2008-07-10 | 4エスツェー アクチェンゲゼルシャフト | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
US7423150B2 (en) | 2003-10-16 | 2008-09-09 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
US7435823B2 (en) | 2004-01-23 | 2008-10-14 | Amgen Inc. | Compounds and methods of use |
JP2008545660A (en) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrropyridine compounds useful as protein kinase inhibitors |
JP2009501130A (en) * | 2005-07-14 | 2009-01-15 | アステラス製薬株式会社 | Heterocyclic Janus Kinase 3 Inhibitor |
JP2009504649A (en) * | 2005-08-08 | 2009-02-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Thiazolopyrimidine kinase inhibitor |
US7514460B2 (en) | 2004-12-22 | 2009-04-07 | 4Sc Ag | Benzazole analogues and uses thereof |
US7576090B2 (en) | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
US7625931B2 (en) | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US7732465B2 (en) | 2005-08-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzimidazoles and methods of their use |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7858623B2 (en) | 2005-04-27 | 2010-12-28 | Amgen Inc. | Substituted amide derivatives and methods of use |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
WO2011103018A1 (en) | 2010-02-18 | 2011-08-25 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US8076488B2 (en) | 2003-02-28 | 2011-12-13 | Bayer Healthcare Llc | Bicyclic urea derivatives useful in the treatment of cancer and other disorders |
WO2011159124A2 (en) * | 2010-06-18 | 2011-12-22 | 이화여자대학교 산학협력단 | Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8173689B2 (en) | 2006-04-19 | 2012-05-08 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
WO2013056070A3 (en) * | 2011-10-14 | 2013-08-01 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
US8563746B2 (en) | 2008-10-29 | 2013-10-22 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8598190B2 (en) | 2008-09-25 | 2013-12-03 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
CN103450093A (en) * | 2013-09-06 | 2013-12-18 | 中国药科大学 | 2-aminobenzimidazoles and applications thereof |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8901143B2 (en) | 2007-04-16 | 2014-12-02 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
US8921405B2 (en) | 2009-03-05 | 2014-12-30 | Orexo Ab | Compounds |
CN105061331A (en) * | 2015-09-21 | 2015-11-18 | 董瑞兰 | Pharmaceutical composition for eliminating phlegm for children |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2016016421A1 (en) * | 2014-07-31 | 2016-02-04 | Institut Pasteur Korea | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors |
CN105949178A (en) * | 2015-03-09 | 2016-09-21 | 张锐豪 | Benzimidazole compound, and preparation method, intermediate and application thereof |
WO2016198322A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
US9573969B2 (en) | 2014-09-12 | 2017-02-21 | Novartis Ag | Compounds and compositions as kinase inhibitors |
WO2017049462A1 (en) * | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | Novel flt3 kinase inhibitor and uses thereof |
WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US9957235B2 (en) | 2014-02-11 | 2018-05-01 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
CN108864151A (en) * | 2010-11-19 | 2018-11-23 | 利亘制药公司 | heterocyclic amine and application thereof |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US10172840B2 (en) | 2014-12-01 | 2019-01-08 | Vtv Therapeutics Llc | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof |
US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
CN112759588A (en) * | 2019-10-21 | 2021-05-07 | 复旦大学 | Benzo five-membered heterocyclic amine derivative and application thereof |
WO2021226261A1 (en) * | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2022140527A1 (en) * | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2022133098A3 (en) * | 2020-12-16 | 2022-07-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
EP3911319A4 (en) * | 2019-01-18 | 2022-09-21 | vTv Therapeutics LLC | Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications |
WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2024088379A1 (en) * | 2022-10-27 | 2024-05-02 | 香港科技大学 | Tumor treatment or prevention method |
WO2024088377A1 (en) * | 2022-10-27 | 2024-05-02 | 香港科技大学 | Pyrimidopyrrole analog |
US12011449B2 (en) | 2016-09-19 | 2024-06-18 | Novartis Ag | Therapeutic combinations comprising a c-RAF inhibitor |
US12036227B2 (en) | 2017-05-02 | 2024-07-16 | Novartis Ag | Combination therapy |
US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7714009B2 (en) * | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
MXPA06013996A (en) * | 2004-06-02 | 2007-02-08 | Takeda Pharmaceutical | Fused heterocyclic compound. |
US8110595B2 (en) * | 2004-06-17 | 2012-02-07 | Cytokinetics, Inc. | Ureas and their use in the treatment of heart failure |
WO2007124345A2 (en) * | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
KR20100017866A (en) * | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r inhibitors, compositions, and methods of use |
WO2008150015A1 (en) * | 2007-06-05 | 2008-12-11 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
CA2703257C (en) * | 2007-10-29 | 2013-02-19 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
US20120058984A1 (en) * | 2009-03-17 | 2012-03-08 | Catherine Mary Alder | Pyrimidine derivatives used as itk inhibitors |
GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
WO2014038882A1 (en) * | 2012-09-07 | 2014-03-13 | 한국생명공학연구원 | Novel compound, and use thereof for inhibiting interleukin-1 beta or interleukin-6 |
US9988386B2 (en) * | 2013-05-30 | 2018-06-05 | Kata Pharmaceuticals, Inc. | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof |
CN105085388B (en) * | 2015-09-06 | 2018-07-13 | 合肥华方医药科技有限公司 | A kind of synthetic method of Sorafenib intermediate |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
CN106008336A (en) * | 2016-06-29 | 2016-10-12 | 上海工程技术大学 | Preparation method of 4-chloro-6,7-dimethoxyquinoline |
WO2018069893A1 (en) * | 2016-10-14 | 2018-04-19 | Novartis Ag | Methods for treating ocular disease using inhibitors of csf-1r |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2710295A (en) * | 1949-12-23 | 1955-06-07 | Ciba Pharm Prod Inc | Process for the manufacture of quinazoline compounds |
EP0419210A1 (en) * | 1989-09-22 | 1991-03-27 | Pfizer Inc. | Novel benzimidazole compounds and their use |
SK278131B6 (en) * | 1993-06-18 | 1996-02-07 | Eva Sidoova | 3-(2-alkylthio-6-benzothiazolylaminomethyl)-2-benzoxazolinthiones and method of their preparation |
WO1996035681A1 (en) * | 1995-05-12 | 1996-11-14 | Dr. Karl Thomae Gmbh | Benzothiazoles and benzoxazoles, as well as drugs containing them, their use and methods of preparing them |
WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
WO2003074515A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57149341A (en) | 1981-03-13 | 1982-09-14 | Dainippon Ink & Chem Inc | Colorant for polyolefin |
KR20060097105A (en) * | 2003-07-22 | 2006-09-13 | 얀센 파마슈티카 엔.브이. | Quinolinone derivatives as inhibitors of c-fms kinase |
WO2005073224A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
WO2007025798A2 (en) * | 2005-07-27 | 2007-03-08 | F. Hoffmann-La Roche Ag | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
-
2004
- 2004-03-19 US US10/804,915 patent/US7531553B2/en active Active
- 2004-03-22 EP EP04758050A patent/EP1638954A1/en not_active Withdrawn
- 2004-03-22 CA CA002518909A patent/CA2518909A1/en not_active Abandoned
- 2004-03-22 JP JP2006507472A patent/JP2006520805A/en not_active Withdrawn
- 2004-03-22 AU AU2004223827A patent/AU2004223827B2/en not_active Ceased
- 2004-03-22 WO PCT/US2004/008809 patent/WO2004085425A1/en active Search and Examination
- 2004-03-22 MX MXPA05010086A patent/MXPA05010086A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2710295A (en) * | 1949-12-23 | 1955-06-07 | Ciba Pharm Prod Inc | Process for the manufacture of quinazoline compounds |
EP0419210A1 (en) * | 1989-09-22 | 1991-03-27 | Pfizer Inc. | Novel benzimidazole compounds and their use |
SK278131B6 (en) * | 1993-06-18 | 1996-02-07 | Eva Sidoova | 3-(2-alkylthio-6-benzothiazolylaminomethyl)-2-benzoxazolinthiones and method of their preparation |
WO1996035681A1 (en) * | 1995-05-12 | 1996-11-14 | Dr. Karl Thomae Gmbh | Benzothiazoles and benzoxazoles, as well as drugs containing them, their use and methods of preparing them |
WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
WO2003074515A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
Non-Patent Citations (9)
Title |
---|
BULL. POL. ACAD. SCI. CHEM., vol. 50, no. 3, 2002, pages 309 - 322 * |
CHEM. ZVESTI, vol. 33, 1979, pages 542 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002289773 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002289774 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002289775 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002289776 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SIDOOVA, EVA ET AL: "Preparation of 3-(2-alkylthio-6-benzothiazolylaminomethyl)-2- benzoxazolinethiones as algicides", XP002289777, retrieved from STN Database accession no. 1997:189834 * |
DISS. PHARM., vol. 13, 1961, pages 127 - 130 * |
PHOSPHORUS, SULFUR SILICON RELAT ELEM., vol. 48, no. 1-4, 1990, pages 149 - 155 * |
Cited By (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US8071616B2 (en) | 2002-02-11 | 2011-12-06 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US8614330B2 (en) | 2002-03-29 | 2013-12-24 | Novartis Vaccines And Diagnostics, Inc. | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase |
US7728010B2 (en) | 2002-03-29 | 2010-06-01 | Novartis Vaccines And Diagnostics, Inc. | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
US8076488B2 (en) | 2003-02-28 | 2011-12-13 | Bayer Healthcare Llc | Bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
EP2258365A1 (en) * | 2003-03-28 | 2010-12-08 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
WO2004087153A3 (en) * | 2003-03-28 | 2005-03-17 | Chiron Corp | Use of organic compounds for immunopotentiation |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
EA011890B1 (en) * | 2003-09-29 | 2009-06-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | Substituted benzazoles and use thereof as inhibitors of raf kinase |
WO2005032548A1 (en) * | 2003-09-29 | 2005-04-14 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
US7423150B2 (en) | 2003-10-16 | 2008-09-09 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
US8415382B2 (en) | 2003-10-16 | 2013-04-09 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase |
AU2004285643B2 (en) * | 2003-10-24 | 2011-06-02 | Merck Patent Gmbh | Benzimidazolyl derivatives |
US7470702B2 (en) | 2003-10-24 | 2008-12-30 | Merck Patent Gmbh | Benzimidazoles |
WO2005042520A1 (en) * | 2003-10-24 | 2005-05-12 | Merck Patent Gmbh | Benzimidazolyl derivatives |
US8178557B2 (en) | 2004-01-23 | 2012-05-15 | Amgen Inc. | Compounds and methods of use |
US7435823B2 (en) | 2004-01-23 | 2008-10-14 | Amgen Inc. | Compounds and methods of use |
US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
JP2007518823A (en) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | Quinoline, quinazoline, pyridine, and pyrimidine compounds and their use in the treatment of inflammation, angiogenesis, and cancer |
WO2005073224A3 (en) * | 2004-01-23 | 2005-09-29 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
WO2005073224A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
JP2008517890A (en) * | 2004-10-22 | 2008-05-29 | キャンサー・リサーチ・テクノロジー・リミテッド | Imidazo [4,5-B] pyridin-2-one and oxazolo [4,5-B] pyridin-2-one compounds and their analogs as therapeutic compounds |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
US7514460B2 (en) | 2004-12-22 | 2009-04-07 | 4Sc Ag | Benzazole analogues and uses thereof |
JP2008524282A (en) * | 2004-12-22 | 2008-07-10 | 4エスツェー アクチェンゲゼルシャフト | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
EA013863B1 (en) * | 2004-12-27 | 2010-08-30 | 4-Эс-Ц АГ | 2,5 and 2,6-substituted benzazole analogues useful as protein kinase inhibitors |
US7576090B2 (en) | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
JP2008525361A (en) * | 2004-12-27 | 2008-07-17 | 4エスツェー アクチェンゲゼルシャフト | 2,5 and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
WO2006069740A1 (en) * | 2004-12-27 | 2006-07-06 | 4Sc Ag | 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors |
EP1674466A1 (en) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
CN101090899B (en) * | 2004-12-27 | 2015-09-09 | 4Sc股份公司 | As 2,5 and 2,6 disubstituted benzazole analogues of kinases inhibitor |
AU2005321517B2 (en) * | 2004-12-27 | 2011-09-29 | 4Sc Ag | 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7625931B2 (en) | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
US8088794B2 (en) | 2005-04-27 | 2012-01-03 | Amgen Inc. | Substituted amide derivatives and methods of use |
US8685983B2 (en) | 2005-04-27 | 2014-04-01 | Amgen Inc. | Method of treating cancer with substituted amide derivatives |
US7858623B2 (en) | 2005-04-27 | 2010-12-28 | Amgen Inc. | Substituted amide derivatives and methods of use |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
JP2008545660A (en) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrropyridine compounds useful as protein kinase inhibitors |
JP2009179644A (en) * | 2005-05-20 | 2009-08-13 | Vertex Pharmaceut Inc | Pyrrolopyridine compound useful as inhibitor for protein kinase |
EP2354139A1 (en) * | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
JP2009501130A (en) * | 2005-07-14 | 2009-01-15 | アステラス製薬株式会社 | Heterocyclic Janus Kinase 3 Inhibitor |
JP2009504649A (en) * | 2005-08-08 | 2009-02-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Thiazolopyrimidine kinase inhibitor |
US7767820B2 (en) | 2005-08-30 | 2010-08-03 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzimidazoles and methods of preparation |
US7732465B2 (en) | 2005-08-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzimidazoles and methods of their use |
US8592459B2 (en) | 2005-08-30 | 2013-11-26 | Novartis Ag | Substituted benzimidazoles and methods of their use |
CN102633783A (en) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
US8377983B2 (en) | 2006-02-10 | 2013-02-19 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
US7820821B2 (en) | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
EP2295432A1 (en) * | 2006-02-10 | 2011-03-16 | TransTech Pharma Inc. | Process for the preparation of aminobenzimidazole derivatives |
WO2007095124A3 (en) * | 2006-02-10 | 2007-11-01 | Transtech Pharma Inc | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
US8710048B2 (en) | 2006-04-19 | 2014-04-29 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
US8173689B2 (en) | 2006-04-19 | 2012-05-08 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
US8901143B2 (en) | 2007-04-16 | 2014-12-02 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
US8703796B2 (en) | 2008-09-25 | 2014-04-22 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents |
US8598190B2 (en) | 2008-09-25 | 2013-12-03 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US9040565B2 (en) | 2008-09-25 | 2015-05-26 | Orexo Ab | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents |
US8916599B2 (en) | 2008-09-25 | 2014-12-23 | Orexo Ab | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8563746B2 (en) | 2008-10-29 | 2013-10-22 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8921405B2 (en) | 2009-03-05 | 2014-12-30 | Orexo Ab | Compounds |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US10570126B2 (en) | 2010-02-18 | 2020-02-25 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US10030011B2 (en) | 2010-02-18 | 2018-07-24 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US10287284B2 (en) | 2010-02-18 | 2019-05-14 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
EP2536285A4 (en) * | 2010-02-18 | 2014-01-22 | High Point Pharmaceuticals Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
EP2536285A1 (en) * | 2010-02-18 | 2012-12-26 | High Point Pharmaceuticals, LLC | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US11649230B2 (en) | 2010-02-18 | 2023-05-16 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US11130753B2 (en) | 2010-02-18 | 2021-09-28 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
WO2011103018A1 (en) | 2010-02-18 | 2011-08-25 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US12091407B2 (en) | 2010-02-18 | 2024-09-17 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
CN102762101A (en) * | 2010-02-18 | 2012-10-31 | 高点制药有限责任公司 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
KR101372721B1 (en) | 2010-06-18 | 2014-03-14 | 이화여자대학교 산학협력단 | New benzoxazol derivatives, the preparation thereof and the pharmaceutical composition comprising the same for Interleukin-6 antagonist |
WO2011159124A3 (en) * | 2010-06-18 | 2012-05-03 | 이화여자대학교 산학협력단 | Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same |
US8614240B2 (en) | 2010-06-18 | 2013-12-24 | Ewha University-Industry Collaboration Foundation | Benzoxazole derivatives having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing the same |
WO2011159124A2 (en) * | 2010-06-18 | 2011-12-22 | 이화여자대학교 산학협력단 | Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US11186593B2 (en) | 2010-11-19 | 2021-11-30 | Ligand Pharmaceuticals Incorporated | Heterocycle amines and uses thereof |
US11773110B2 (en) | 2010-11-19 | 2023-10-03 | Ligand Pharmaceuticals Incorporated | Heterocycle amines and uses thereof |
CN108864151A (en) * | 2010-11-19 | 2018-11-23 | 利亘制药公司 | heterocyclic amine and application thereof |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
US9938261B2 (en) | 2011-10-14 | 2018-04-10 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
TWI650321B (en) * | 2011-10-14 | 2019-02-11 | 美商安比特生物科學公司 | Heterocyclic compound and method of use thereof |
US9452167B2 (en) | 2011-10-14 | 2016-09-27 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
WO2013056070A3 (en) * | 2011-10-14 | 2013-08-01 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
KR20140075010A (en) * | 2011-10-14 | 2014-06-18 | 암비트 바이오사이언시즈 코포레이션 | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
KR102066297B1 (en) | 2011-10-14 | 2020-01-14 | 암비트 바이오사이언시즈 코포레이션 | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
RU2648997C2 (en) * | 2011-10-14 | 2018-03-29 | Эмбит Байосайенсиз Корпорейшн | Heterocyclic compounds and methods of their use |
US8952058B2 (en) | 2011-10-14 | 2015-02-10 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
CN104066730A (en) * | 2011-10-14 | 2014-09-24 | 埃姆比特生物科学公司 | Heterocyclic compounds and methods of use thereof as modulators of type III receptor tyrosine kinases |
AU2012322095B2 (en) * | 2011-10-14 | 2017-06-29 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases |
US10245267B2 (en) | 2013-03-14 | 2019-04-02 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US9694016B2 (en) | 2013-03-14 | 2017-07-04 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US10709712B2 (en) | 2013-03-14 | 2020-07-14 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
CN103450093A (en) * | 2013-09-06 | 2013-12-18 | 中国药科大学 | 2-aminobenzimidazoles and applications thereof |
US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US9957235B2 (en) | 2014-02-11 | 2018-05-01 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
US10442772B2 (en) | 2014-02-11 | 2019-10-15 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
US11447486B2 (en) | 2014-07-31 | 2022-09-20 | Institut Pasteur Korea | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors |
WO2016016421A1 (en) * | 2014-07-31 | 2016-02-04 | Institut Pasteur Korea | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors |
CN106879256A (en) * | 2014-07-31 | 2017-06-20 | 韩国巴斯德研究所 | 2 aminobenzimidazole derivatives and its application as 5 LOXs and/or prostaglandin-e synthetase inhibitors |
AU2015295248B2 (en) * | 2014-07-31 | 2019-05-16 | Institut Pasteur Korea | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors |
RU2732416C2 (en) * | 2014-07-31 | 2020-09-16 | Институт Пастер Корея | 2-amino-benzimidazole derivatives and use thereof as 5-lipoxygenase and/or prostaglandin e-synthase inhibitors |
CN106879256B (en) * | 2014-07-31 | 2021-08-03 | 韩国巴斯德研究所 | 2-amino-benzimidazole derivatives and their use as inhibitors of 5-lipoxygenase and/or prostaglandin e synthase |
US9809610B2 (en) | 2014-09-12 | 2017-11-07 | Novartis Ag | Compounds and compositions as kinase inhibitors |
US9573969B2 (en) | 2014-09-12 | 2017-02-21 | Novartis Ag | Compounds and compositions as kinase inhibitors |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US10172840B2 (en) | 2014-12-01 | 2019-01-08 | Vtv Therapeutics Llc | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof |
US10898475B2 (en) | 2014-12-01 | 2021-01-26 | Vtv Therapeutics Llc | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof |
US10463652B2 (en) | 2014-12-01 | 2019-11-05 | Vtv Therapeutics Llc | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof |
CN105949178B (en) * | 2015-03-09 | 2020-05-26 | 西格莱(苏州)生物医药有限公司 | Benzimidazole compound, preparation method, intermediate and application thereof |
CN105949178A (en) * | 2015-03-09 | 2016-09-21 | 张锐豪 | Benzimidazole compound, and preparation method, intermediate and application thereof |
US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
US11858938B2 (en) | 2015-03-16 | 2024-01-02 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
WO2016198322A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
US10370339B2 (en) | 2015-06-08 | 2019-08-06 | Bayer Pharma Aktiengesellschaft | N-Methylbenzimidazoles as mIDH1 inhibitors |
WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
CN108026053A (en) * | 2015-07-21 | 2018-05-11 | 拜耳制药股份公司 | Glyoxaline compound as the fusion of mIDH1 inhibitor |
WO2017012967A1 (en) * | 2015-07-21 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
CN108026053B (en) * | 2015-07-21 | 2021-10-08 | 德国癌症研究公共权益基金会 | Fused imidazoles as mIDH1 inhibitors |
EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
CN105061331A (en) * | 2015-09-21 | 2015-11-18 | 董瑞兰 | Pharmaceutical composition for eliminating phlegm for children |
WO2017049462A1 (en) * | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | Novel flt3 kinase inhibitor and uses thereof |
WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
US12011449B2 (en) | 2016-09-19 | 2024-06-18 | Novartis Ag | Therapeutic combinations comprising a c-RAF inhibitor |
US12036227B2 (en) | 2017-05-02 | 2024-07-16 | Novartis Ag | Combination therapy |
EP3911319A4 (en) * | 2019-01-18 | 2022-09-21 | vTv Therapeutics LLC | Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications |
CN112759588A (en) * | 2019-10-21 | 2021-05-07 | 复旦大学 | Benzo five-membered heterocyclic amine derivative and application thereof |
CN115996917A (en) * | 2020-05-06 | 2023-04-21 | 艾捷斯治疗公司 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2021226261A1 (en) * | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2022133098A3 (en) * | 2020-12-16 | 2022-07-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
WO2022140527A1 (en) * | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
WO2024088377A1 (en) * | 2022-10-27 | 2024-05-02 | 香港科技大学 | Pyrimidopyrrole analog |
WO2024088379A1 (en) * | 2022-10-27 | 2024-05-02 | 香港科技大学 | Tumor treatment or prevention method |
Also Published As
Publication number | Publication date |
---|---|
US7531553B2 (en) | 2009-05-12 |
JP2006520805A (en) | 2006-09-14 |
EP1638954A1 (en) | 2006-03-29 |
CA2518909A1 (en) | 2004-10-07 |
US20040209892A1 (en) | 2004-10-21 |
MXPA05010086A (en) | 2006-02-10 |
AU2004223827A1 (en) | 2004-10-07 |
AU2004223827B2 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7531553B2 (en) | Heterocyclic compounds and methods of use | |
US7320992B2 (en) | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | |
US7390820B2 (en) | Substituted quinolinone derivatives and methods of use | |
US7307088B2 (en) | Substituted anthranilic amide derivatives and methods of use | |
US7105682B2 (en) | Substituted amine derivatives and methods of use | |
US7101868B2 (en) | Substituted arylamine derivatives and methods of use | |
US8247556B2 (en) | Method for preparing 6-substituted-7-aza-indoles | |
US20020147198A1 (en) | Substituted arylamine derivatives and methods of use | |
AU2002248339A1 (en) | Substituted Arylamine Derivatives and Methods of Use | |
AU2002253890A1 (en) | Substituted Amine Derivatives and Methods of Use | |
CA2903040A1 (en) | Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and their use for the treatment of egfr / erbb2 related disorders | |
US9346801B2 (en) | Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2518909 Country of ref document: CA Ref document number: 2004223827 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006507472 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/010086 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2004223827 Country of ref document: AU Date of ref document: 20040322 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004223827 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004758050 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004758050 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) |